<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">63326</article-id><article-id pub-id-type="doi">10.7554/eLife.63326</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-209790"><name><surname>Torrence</surname><given-names>Margaret E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2133-8599</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209792"><name><surname>MacArthur</surname><given-names>Michael R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209791"><name><surname>Hosios</surname><given-names>Aaron M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209793"><name><surname>Valvezan</surname><given-names>Alexander J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-17353"><name><surname>Asara</surname><given-names>John M</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-209794"><name><surname>Mitchell</surname><given-names>James R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-3347"><name><surname>Manning</surname><given-names>Brendan D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3895-5956</contrib-id><email>bmanning@hsph.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution>Department of Molecular Metabolism, Harvard T. H. Chan School of Public Health</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH) Zurich</institution><addr-line><named-content content-type="city">Zurich</named-content></addr-line><country>Switzerland</country></aff><aff id="aff3"><label>3</label><institution>Center for Advanced Biotechnology and Medicine, Department of Pharmacology, Rutgers Robert Wood Johnson Medical School</institution><addr-line><named-content content-type="city">Piscataway</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Division of Signal Transduction, Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School</institution><addr-line><named-content content-type="city">Boston</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ron</surname><given-names>David</given-names></name><role>Senior Editor</role><aff><institution>University of Cambridge</institution><country>United Kingdom</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>01</day><month>03</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e63326</elocation-id><history><date date-type="received" iso-8601-date="2020-09-22"><day>22</day><month>09</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2021-02-26"><day>26</day><month>02</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Torrence et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Torrence et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-63326-v2.pdf"/><abstract><p>The mechanistic target of rapamycin complex 1 (mTORC1) stimulates a coordinated anabolic program in response to growth-promoting signals. Paradoxically, recent studies indicate that mTORC1 can activate the transcription factor ATF4 through mechanisms distinct from its canonical induction by the integrated stress response (ISR). However, its broader roles as a downstream target of mTORC1 are unknown. Therefore, we directly compared ATF4-dependent transcriptional changes induced upon insulin-stimulated mTORC1 signaling to those activated by the ISR. In multiple mouse embryo fibroblast and human cancer cell lines, the mTORC1-ATF4 pathway stimulated expression of only a subset of the ATF4 target genes induced by the ISR, including genes involved in amino acid uptake, synthesis, and tRNA charging. We demonstrate that ATF4 is a metabolic effector of mTORC1 involved in both its established role in promoting protein synthesis and in a previously unappreciated function for mTORC1 in stimulating cellular cystine uptake and glutathione synthesis.</p></abstract><abstract abstract-type="executive-summary"><title>eLife digest</title><p>When building healthy tissue, the human body must carefully control the growth of new cells to prevent them from becoming cancerous. A core component of this regulation is the protein mTORC1, which responds to various growth-stimulating factors and nutrients, and activates the chemical reactions cells need to grow. Part of this process involves controlling ‘nutrient-sensing transcription factors’ – proteins that regulate the activity of specific genes based on the availability of different nutrients.</p><p>One of these nutrient-sensing transcription factors, ATF4, has recently been shown to be involved in some of the processes triggered by mTORC1. The role this factor plays in how cells respond to stress – such as when specific nutrients are depleted, protein folding is disrupted or toxins are present – is well-studied. But how it reacts to the activation of mTORC1 is less clear. To bridge this gap, Torrence et al. studied mouse embryonic cells and human prostate cancer cells grown in the laboratory, to see whether mTORC1 influenced the behavior of ATF4 differently than cellular stress.</p><p>Cells were treated either with insulin, which activates mTORC1, or an antibiotic that sparks the stress response. The cells were then analyzed using a molecular tool to see which genes were switched on by ATF4 following treatment. This revealed that less than 10% of the genes activated by ATF4 during cellular stress are also activated in response to mTORC1-driven growth.</p><p>Many of the genes activated in both scenarios were involved in synthesizing and preparing the building blocks that make up proteins. This was consistent with the discovery that ATF4 helps mTORC1 stimulate growth by promoting protein synthesis. Torrence et al. also found that mTORC1’s regulation of ATF4 stimulated the synthesis of glutathione, the most abundant antioxidant in cells.</p><p>The central role mTORC1 plays in controlling cell growth means it is important to understand how it works and how it can lead to uncontrolled growth in human diseases. mTORC1 is activated in many overgrowth syndromes and the majority of human cancers. These new findings could provide insight into how tumors coordinate their drive for growth while adapting to cellular stress, and reveal new drug targets for cancer treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>metabolism</kwd><kwd>rapamycin</kwd><kwd>mTOR</kwd><kwd>integrated stress response</kwd><kwd>xCT</kwd><kwd>cystine</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd><kwd>Rat</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35-CA197459</award-id><principal-award-recipient><name><surname>Manning</surname><given-names>Brendan D</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P01-CA120964</award-id><principal-award-recipient><name><surname>Asara</surname><given-names>John M</given-names></name><name><surname>Manning</surname><given-names>Brendan D</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id><institution>U.S. Department of Defense</institution></institution-wrap></funding-source><award-id>W81XWH-18-1- 0659</award-id><principal-award-recipient><name><surname>Manning</surname><given-names>Brendan D</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32-ES016645</award-id><principal-award-recipient><name><surname>Torrence</surname><given-names>Margaret E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F31-CA228332</award-id><principal-award-recipient><name><surname>Torrence</surname><given-names>Margaret E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Larimar Therapeutics</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Manning</surname><given-names>Brendan D</given-names></name><name><surname>Mitchell</surname><given-names>James R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>ATF4 is a metabolic effector of mTORC1 signaling, co-opted to induce gene targets involved in amino acid synthesis, uptake, and tRNA charging, contributing to mTORC1-driven protein and glutathione synthesis.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Pro-growth signals in the form of growth factors, hormones, and nutrients impinge on cellular metabolic programs in a coordinated fashion involving both acute, post-translational regulation and transcriptional control of nutrient transporters and metabolic enzymes. The mechanistic target of rapamycin complex 1 (mTORC1) acts as a central point of integration for these signals and propagates a downstream metabolic response that increases anabolic processes while decreasing specific catabolic processes. Through a variety of downstream effectors, mTORC1 stimulates the synthesis of the major macromolecules comprising cellular biomass, including protein, lipid, and nucleic acids, along with metabolic and adaptive pathways that support this anabolic program (<xref ref-type="bibr" rid="bib66">Valvezan and Manning, 2019</xref>).</p><p>A particularly interesting feature of this coordinated metabolic program downstream of mTORC1 is the co-opting of key nutrient-sensing transcription factors that are established to be activated, independent of mTORC1, in response to depletion of specific nutrients (<xref ref-type="bibr" rid="bib64">Torrence and Manning, 2018</xref>). In their canonical roles, these transcription factors serve to mount an adaptive response by upregulating genes that allow cells to overcome the specific nutrient deficiency. Perhaps the best characterized of these transcription factors with dual regulation is the hypoxia-inducible factor 1 (HIF1) comprising the labile HIF1α protein heterodimerized with the aryl hydrocarbon receptor nuclear translocator (ARNT or HIF1β). Oxygen depletion (i.e., hypoxia) results in the rapid stabilization of HIF1α and allows the HIF1 heterodimer to induce genes involved in glucose uptake, glycolysis, and angiogenesis to adapt to hypoxia and decrease mitochondrial respiration (<xref ref-type="bibr" rid="bib43">Nakazawa et al., 2016</xref>). On the other hand, in response to upstream growth factor signaling pathways, activation of mTORC1 stimulates an increase in HIF1α protein synthesis, leading to elevated expression of HIF1 gene targets (<xref ref-type="bibr" rid="bib5">Brugarolas et al., 2003</xref>; <xref ref-type="bibr" rid="bib13">Düvel et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Hudson et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Laughner et al., 2001</xref>; <xref ref-type="bibr" rid="bib62">Thomas et al., 2006</xref>; <xref ref-type="bibr" rid="bib81">Zhong et al., 2000</xref>). The result is an mTORC1-mediated increase in glucose uptake and glycolysis even when oxygen is not limiting (e.g., normoxia), a process referred to as aerobic glycolysis, which can support the production of biosynthetic precursors in the form of glycolytic intermediates. Similarly, the sterol regulatory element (SRE)-binding protein (SREBP) family of transcription factors are independently regulated by both adaptive nutrient signals and growth signals controlling mTORC1. The SREBPs are canonically activated upon sterol depletion and induce expression of the enzymes required for de novo synthesis of fatty acid and sterol lipids (<xref ref-type="bibr" rid="bib26">Horton et al., 2002</xref>). However, insulin and growth factor signaling can also induce lipid synthesis via mTORC1-stimulated activation of SREBP and its lipogenic gene targets (<xref ref-type="bibr" rid="bib13">Düvel et al., 2010</xref>; <xref ref-type="bibr" rid="bib45">Owen et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Peterson et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Porstmann et al., 2008</xref>). Recent studies have suggested that the regulation of nutrient-sensing transcription factors by mTORC1 signaling extends to the activating transcription factor 4 (ATF4) (<xref ref-type="bibr" rid="bib1">Adams, 2007</xref>; <xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">Torrence and Manning, 2018</xref>).</p><p>ATF4 is a basic leucine zipper (bZIP) transcription factor that is selectively translated in response to specific forms of cellular stress to induce the expression of genes involved in adaptation to stress (<xref ref-type="bibr" rid="bib69">Walter and Ron, 2011</xref>). This adaptive program is referred to as the integrated stress response (ISR) and is initiated by stress-activated protein kinases, including general control nonderepressible 2 (GCN2) activated upon amino acid deprivation and protein kinase RNA-like endoplasmic reticulum kinase (PERK) activated by ER stress, among others, which phosphorylate eIF2α on Ser51 (<xref ref-type="bibr" rid="bib20">Harding et al., 2000</xref>). Phosphorylation of eIF2α serves to globally attenuate mRNA translation to conserve amino acids and energy and decrease the cellular protein load as one adaptive measure to overcome these stresses (<xref ref-type="bibr" rid="bib7">Clemens, 1996</xref>). Importantly, a small number of mRNAs, including that encoding ATF4, exhibit increased translation upon eIF2α-Ser51 phosphorylation (<xref ref-type="bibr" rid="bib67">Vattem and Wek, 2004</xref>). The stress-induced increase in ATF4 leads to the expression of a canonical set of ATF4 target genes, including those involved in nonessential amino acid (NEAA) biosynthesis and amino acid transport, as part of the adaptive cellular response specific to stresses such as amino acid depletion (<xref ref-type="bibr" rid="bib21">Harding et al., 2003</xref>).</p><p>ATF4 functions in heterodimers with other bZIP transcription factors and also co-regulates many of its target genes with additional transcription factors as part of the cellular stress response (<xref ref-type="bibr" rid="bib44">Newman and Keating, 2003</xref>; <xref ref-type="bibr" rid="bib72">Wortel et al., 2017</xref>). However, whether and how the many distinct upstream stresses that activate ATF4 influence its heterodimerization partners and the induction of specific sets of genes is not well understood.</p><p>While ATF4 is a major downstream effector of the ISR, evidence has emerged that ATF4 can also be activated by pro-growth signals that stimulate mTORC1 signaling (<xref ref-type="bibr" rid="bib1">Adams, 2007</xref>; <xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>), and cis-regulatory elements for ATF4 binding are enriched in the promoters of mTORC1-induced genes (<xref ref-type="bibr" rid="bib13">Düvel et al., 2010</xref>). Importantly, the mTORC1-mediated activation of ATF4 involves its increased translation in a manner that is independent of the ISR and phosphorylation of eIF2α (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Park et al., 2017</xref>). These findings suggest that, similar to HIF1 and SREBP, ATF4 induction may be mobilized as part of the broader anabolic program downstream of mTORC1. Indeed, our previous findings indicate that mTORC1 promotes de novo purine synthesis, in part, through induction of mitochondrial one-carbon metabolism via ATF4 activation and expression of its gene target MTHFD2 (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>).</p><p>How the ATF4-dependent gene program compares between its adaptive role in the ISR and its activation as a downstream effector of mTORC1 signaling and whether ATF4 contributes to established or new functions of mTORC1 are unknown (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Here, we find that the mTORC1-ATF4 program represents a small subset of ATF4-dependent genes induced by ER stress and includes genes encoding the enzymes required for tRNA charging, NEAA synthesis, and amino acid uptake. Consistent with regulation of these enzymes by mTORC1 through ATF4, ATF4 contributes to the induction of protein synthesis downstream of mTORC1. We also find that mTORC1 signaling promotes glutathione synthesis through ATF4 and its specific regulation of the cystine transporter SLC7A11. Thus, ATF4 is an anabolic effector of mTORC1 signaling, necessary for both its canonical regulation of protein synthesis and its induced synthesis of glutathione, the most abundant antioxidant in cells.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Mechanistic target of rapamycin complex 1 (mTORC1) signaling activates a subset of activating transcription factor 4 (ATF4)-dependent genes also activated by the integrated stress response (ISR).</title><p>(<bold>A</bold>) Schematic of the dual regulation of ATF4 and the unknowns addressed in this study. (<bold>B</bold>) Immunoblots of parallel lysates from RNA-seq experiment. <italic>Atf4<sup>+/+</sup></italic> and <italic>Atf4<sup>-/-</sup></italic> mouse embryo fibroblasts were treated, as indicated, with insulin (500 nM, 16 hr) or rapamycin (20 nM, 30 min) prior to insulin (left) or with tunicamycin (2 μg/mL) for 4, 8, or 16 hr (right). Insulin response is quantified in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. (<bold>C</bold>) Venn diagram depicting number and overlap of mTORC1- and ISR-induced transcripts, including those increased with insulin (red), decreased relative to insulin with rapamycin (green), and increased with 4 hr tunicamycin (orange), and those dependent on ATF4 within these categories (purple), all with p-values &lt;0.05. Only 61 ATF4-dependent genes overlap between those significantly induced by insulin in a rapamycin-sensitive manner and those induced by tunicamycin. Gene lists per category are provided in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. (<bold>D</bold>) KEGG enrichment of the shared mTORC1- and ISR-induced ATF4 target genes. p-Values provided were false discovery rate corrected. (<bold>E</bold>) Plot of -log<sub>10</sub>p<italic>-</italic>values of 774 ATF4-dependent tunicamycin-induced genes. ATF4-dependent genes induced by both mTORC1 signaling and tunicamycin treatment (shared ISR and mTORC1) are shown in red. (<bold>F</bold>) The 61 ATF4-dependent genes induced by both mTORC1 (i.e., rapamycin-sensitive insulin stimulation) and tunicamycin treatment are shown ranked from left to right in order of greatest log<sub>2</sub>-fold change with insulin (red bars), with the corresponding tunicamycin-induced changes superimposed (white bars) (n = 4). Error bars depict 95% confidence intervals.</p><p> <supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Gene lists from <xref ref-type="fig" rid="fig1">Figure 1C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63326-fig1-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Quantification of immunoblot shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig1-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>mTORC1 signaling activates a subset of ATF4-dependent genes also activated by the ISR</title><p>To identify the ATF4-dependent gene targets downstream of mTORC1, we compared the insulin-induced, rapamycin-sensitive transcripts between wild-type MEFs and those with biallelic loss of ATF4 via CRISPR/Cas9 gene deletion (see Materials and methods). Consistent with our previous studies (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>), insulin stimulated an increase in ATF4 protein in MEFs, which was decreased with rapamycin (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In parallel, these cells were treated with a time course of tunicamycin, an inhibitor of N-glycosylation that potently induces ER stress and an increase in ATF4, to identify ATF4 gene targets downstream of the ISR. RNA-seq analysis revealed that 20% of transcripts (253 total) significantly upregulated upon insulin stimulation were significantly blocked in their induction with rapamycin treatment. Approximately 30% of these mTORC1-regulated genes (77 total) lost their insulin responsiveness with ATF4 deletion. In comparison, 36% of transcripts significantly induced with tunicamycin treatment at 4 hr were dependent on ATF4 (774 total). Importantly, the expression of just 61 genes was found to overlap between these two modes of ATF4 regulation, being ATF4 dependent in response to both mTORC1 activation and the ISR (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p><p>The RNA-seq analysis demonstrated that only 8% of ATF4 gene targets induced by ER stress were also significantly stimulated by mTORC1 signaling (e.g., insulin induced and rapamycin sensitive). Interestingly, these 61 shared genes showed significant KEGG pathway enrichment for aminoacyl tRNA biosynthesis, amino acid metabolism, and one-carbon metabolism (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). The genes shared between the ISR and mTORC1 signaling were greatly enriched among those exhibiting the most significant increase upon tunicamycin treatment, with 75% (46 genes) lying within the top 100 of the 774 tunicamycin-induced genes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). It is worth noting that many of the top ATF4-dependent genes that scored as being induced by the ISR alone showed some degree of rapamycin-sensitive induction with insulin but did not reach statistical significance in the RNA-seq analyses. These data indicate that the subset of ATF4-dependent genes induced by mTORC1 signaling largely comprised those that are also most sensitive to ATF4 induction by the ISR. Among the 61 shared ATF4-dependent transcripts, those involved in amino acid synthesis and transport, one-carbon metabolism, and aminoacyl tRNA charging often displayed comparable fold changes between insulin stimulation and tunicamycin treatment, while canonical genes of the ER stress response, such as <italic>Herpud1</italic> and <italic>Ddit3/Chop,</italic> showed much greater induction with tunicamycin (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In addition to aminoacyl tRNA synthetase genes, expression of the <italic>Xpot</italic> gene encoding Exportin-T, which is the major Ran GTPase family member for nuclear to cytosolic export of mature tRNAs (<xref ref-type="bibr" rid="bib2">Arts et al., 1998</xref>; <xref ref-type="bibr" rid="bib32">Kutay et al., 1998</xref>), was found to be similarly regulated by ATF4 in response to mTORC1 and ISR activation. Transcripts encoding known negative regulators of mTORC1 signaling are also among these 61 shared ATF4-induced genes, including <italic>Ddit4/Redd1</italic> and <italic>Sesn2</italic> (<xref ref-type="bibr" rid="bib6">Brugarolas et al., 2004</xref>; <xref ref-type="bibr" rid="bib9">Condon et al., 2021</xref>; <xref ref-type="bibr" rid="bib36">Lee et al., 2010</xref>; <xref ref-type="bibr" rid="bib52">Reiling and Hafen, 2004</xref>; <xref ref-type="bibr" rid="bib71">Wolfson et al., 2016</xref>). These targets likely contribute to the ATF4-dependent inhibition of mTORC1 signaling (S6K1 phosphorylation) observed upon tunicamycin treatment (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), while in the context of mTORC1 signaling, these ATF4 targets might play a role in negative feedback regulation of mTORC1. These data suggest that a specific subset of ATF4-dependent ISR-induced genes are likewise regulated by growth factor signaling through mTORC1 and are enriched for specific processes including aminoacyl tRNA synthesis, amino acid synthesis and uptake, and one-carbon metabolism.</p><p>ATF4 is known to form heterodimers with other bZIP transcription factors to engage its gene targets, while also co-regulating genes with transcription factors that bind additional promoter elements (<xref ref-type="bibr" rid="bib30">Kilberg et al., 2009</xref>; <xref ref-type="bibr" rid="bib44">Newman and Keating, 2003</xref>; <xref ref-type="bibr" rid="bib72">Wortel et al., 2017</xref>). Thus, we used bioinformatic tools to determine whether the promoters of ATF4 gene targets shared between the ISR and mTORC1 signaling might be distinct from those induced by the ISR alone. Indeed, CiiiDER analysis (<xref ref-type="bibr" rid="bib15">Gearing et al., 2019</xref>) revealed that there are predicted promoter-binding sequences that distinguish the 61 shared target genes from the top 200 ATF4-dependent genes induced by the ISR alone (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>). Regulatory elements for the C/EBP family of transcription factors, which are well established to heterodimerize with ATF4 to induce its canonical downstream targets (<xref ref-type="bibr" rid="bib8">Cohen et al., 2015</xref>; <xref ref-type="bibr" rid="bib14">Ebert et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Huggins et al., 2015</xref>), were the most enriched in the promoters of ATF4 gene targets with shared regulation. On the other hand, binding elements for the TEAD family of transcription factors, which function with YAP/TAZ in the Hippo signaling pathway, were enriched in the promoters of ATF4-dependent gene targets significantly induced only by tunicamycin, consistent with published work indicating a functional connection between the unfolded protein response and YAP-TEAD activation (<xref ref-type="bibr" rid="bib73">Wu et al., 2015</xref>; <xref ref-type="bibr" rid="bib74">Xiao et al., 2019</xref>). We next analyzed the 61 ATF4-dependent genes with shared regulation for physical evidence of promoter binding of specific transcription factors using the Cistrome Data Browser, a portal for mining existing chromatin immunoprecipitation-DNA sequencing (ChIP-seq) data (<xref ref-type="bibr" rid="bib41">Mei et al., 2017</xref>; <xref ref-type="bibr" rid="bib80">Zheng et al., 2019</xref>). Importantly, this second unbiased analysis also revealed C/EBP isoforms as most commonly binding to the promoters of these genes (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>C/EBP family transcription factors contribute to the regulation of activating transcription factor 4 (ATF4)-dependent genes shared between mechanistic target of rapamycin complex 1 (mTORC1) signaling and the integrated stress response (ISR).</title><p>(<bold>A</bold>) CiiiDER analysis comparing transcription factor-binding elements enriched in the promoters of the top 200 ATF4-dependent genes induced by tunicamycin but not insulin (ISR Only) versus the 61 ATF4-dependent genes induced by both mTORC1 signaling and tunicamycin (Shared ISR and mTORC1). Those sequence elements significantly enriched (p&lt;0.01) are shown in blue or red. Data are provided in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. (<bold>B</bold>) Cistrome analysis of genome-wide chromatin immunoprecipitation studies to identify transcription factors found to bind to the promoters of the ATF4-dependent genes shared in their regulation by mTORC1 and ISR. (<bold>C</bold>) qPCR analysis of the indicated transcripts in <italic>Tsc2</italic><sup>-/-</sup>mouse embryo fibroblasts (MEFs) transfected with control siRNAs (siCT) or those targeting <italic>Atf4, C/EBPα, C/EBPβ, C/EBPδ, C/EBPγ</italic>. Expression relative to siCT for each gene is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). (<bold>D</bold>) Immunoblots of cells treated as in (<bold>C</bold>). (<bold>E</bold>) qPCR analysis of the indicated transcripts in serum-deprived wild-type MEFs treated with insulin (500 nM, 16 hr) after 30 min pretreatment with vehicle or rapamycin (20 nM) following transfection with control siRNAs (siCT) or those targeting <italic>Atf4</italic> or <italic>C/ebpγ</italic>. Expression relative to siCT for each gene is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant. One-way analysis of variance with Holm–Sidak method for multiple comparisons was used to determine statistical significance for (<bold>C, E</bold>).</p><p> <supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Promoter element enrichment data for <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63326-fig2-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig2-v2.tif"/></fig><p>As all members of the C/EBP family have the potential to heterodimerize with ATF4 and contribute to the induction of these gene targets (<xref ref-type="bibr" rid="bib44">Newman and Keating, 2003</xref>), we first determined the effects of siRNA-mediated knockdown of individual isoforms, relative to ATF4 knockdown, on expression of three representative genes in <italic>Tsc2<sup>-/-</sup></italic> MEFs, which exhibit growth factor-independent activation of mTORC1 signaling. This analysis revealed that knockdown of ATF4, C/EBPβ, C/EBPδ, or C/EBPγ each led to decreased transcript levels of the shared mTORC1 and ISR gene targets <italic>Slc7a5</italic>, <italic>Mthfd2</italic>, and <italic>Aars</italic> (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). However, this analysis was complicated by the finding of substantial co-dependence for expression among these bZIP transcription factors, with knockdown of any one of the C/EBP family members or ATF4 significantly changing expression of at least one other family member. C/EBPδ knockdown, for instance, decreased expression of all genes measured, including ATF4, which was also reflected in loss of ATF4 protein (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). It is worth noting that we were unable to identify reliable antibodies to specific C/EBP family members for use in MEFs. Among C/EBP family members, C/EBPγ has been found in other settings to regulate many of the genes revealed in our analysis to be induced through shared regulation of ATF4 (<xref ref-type="bibr" rid="bib28">Huggins et al., 2015</xref>), and its knockdown significantly decreased expression of the three ATF4 target genes tested without effects on ATF4 protein levels (<xref ref-type="fig" rid="fig2">Figure 2C, D</xref>). Based on this finding, we knocked down ATF4 or C/EBPγ in wild-type MEFs and stimulated the cells with insulin in the presence or absence of rapamycin to determine whether C/EBPγ impacted the mTORC1 and ATF4-dependent regulation of these genes. Indeed, knockdown of C/EBPγ attenuated the insulin-induced expression of these genes, albeit to a lesser extent than ATF4 knockdown (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). C/EBPγ knockdown also blocked the ability of insulin to increase ATF4 transcript levels, suggesting that following the induction of ATF4 mRNA translation downstream of mTORC1 (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Park et al., 2017</xref>), it stimulates its own expression via ATF4-C/EBPγ heterodimers. Thus, C/EBPγ and likely other ATF4-binding partners of the C/EBP family contribute to the induction of ATF4 gene targets following mTORC1-mediated activation of ATF4.</p></sec><sec id="s2-2"><title>mTORC1 signaling induces genes involved in amino acid synthesis, transport, and tRNA charging through ATF4 activation</title><p>To validate and expand the findings from the RNA-seq analysis, a NanoString codeset was designed to simultaneously quantify transcripts of genes involved in the enriched processes above (see Materials and methods). As positive and negative controls, respectively, we included the glycolytic targets of HIF1, established previously to be regulated downstream of mTORC1 (<xref ref-type="bibr" rid="bib13">Düvel et al., 2010</xref>), and the mitochondrial tRNA synthetases, not believed to be regulated by ATF4. Using this codeset, we analyzed gene expression in three settings of mTORC1 activation: (1) wild-type MEFs stimulated with insulin in the presence or absence of rapamycin, (2) growth factor-independent activation of mTORC1 via genetic loss of the TSC protein complex in <italic>Tsc2<sup>-/-</sup></italic> MEFs, and (3) <italic>Tsc2<sup>-/-</sup></italic> MEFs with siRNA-mediated knockdown of ATF4 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>). ATF4 protein levels were robustly upregulated with either genetic or insulin-stimulated mTORC1 activation in these settings, with both rapamycin and ATF4-targeting siRNAs blocking this induction (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Interestingly, the majority of transcripts analyzed in the functional categories that encode enzymes of NEAA synthesis, one-carbon metabolism, amino acid transporters, and cytosolic aminoacyl tRNA synthetases (and <italic>Xpot</italic>) were increased with mTORC1 activation in a manner sensitive to both rapamycin and siRNA-mediated knockdown of ATF4. However, the HIF1 targets of glycolysis were mTORC1-regulated but independent of ATF4, and transcripts encoding the mitochondrial tRNA synthetases were reproducibly regulated by neither mTORC1- nor ATF4. We further confirmed the mTORC1- and ATF4-mediated regulation of a representative subset of these transcripts via qPCR (<xref ref-type="fig" rid="fig3">Figure 3B, C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Consistent with previous studies (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Park et al., 2017</xref>), both ATF4 transcript and protein levels were induced by mTORC1 signaling in these settings (<xref ref-type="fig" rid="fig3">Figure 3B–E</xref>). Transcriptional changes in ATF4 gene targets were reflected in corresponding changes in the abundance of representative protein products, with varying degrees of rapamycin sensitivity, likely reflecting inherent differences in the turnover rates of these proteins (<xref ref-type="fig" rid="fig3">Figure 3D, E</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C, D</xref>). We next wanted to confirm that these mTORC1- and ATF4-induced changes were independent of the ISR. While we have shown previously that mTORC1 regulates ATF4 in a manner that is independent of eIF2<italic>α</italic>-S51 phosphorylation (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>), chronic activation of mTORC1 upon loss of TSC2 is known to cause a basal increase in ER stress and activation of the ISR (<xref ref-type="bibr" rid="bib46">Ozcan et al., 2008</xref>). Therefore, we utilized MEFs with endogenous, homozygous knock-in of the <italic>Eif2a-S51A</italic> mutation (<italic>Eif2a<sup>A/A</sup></italic>), which fail to induce ATF4 downstream of cellular stress (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>; <xref ref-type="bibr" rid="bib57">Scheuner et al., 2001</xref>). Consistent with mTORC1-dependent, ISR-independent regulation, insulin increased ATF4 protein levels and expression of its gene targets involved in amino acid synthesis and one-carbon metabolism, amino acid transporters, and aminoacyl tRNA synthetases in a rapamycin-sensitive manner in these cells, as shown by NanoString analysis and confirmed for a subset of genes by qPCR (<xref ref-type="fig" rid="fig3">Figure 3F, G</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). Notably, like insulin stimulation, genetic activation of mTORC1 via siRNA-mediated knockdown of <italic>Tsc2</italic> in the <italic>eIF2α<sup>A/A</sup></italic> MEFs also increased ATF4 protein levels, further confirming that this regulation can occur independent of the ISR (<xref ref-type="fig" rid="fig3">Figure 3H</xref>). Growth factor-independent activation of mTORC1 also occurs upon loss of the PTEN tumor suppressor, and rapamycin was found to decrease ATF4 protein levels and ATF4-dependent expression of representative gene targets in established PTEN-deficient prostate cancer cells, LNCaP and PC3 (<xref ref-type="fig" rid="fig3">Figure 3I–L</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G–J</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Mechanistic target of rapamycin complex 1 (mTORC1) and activating transcription factor 4 (ATF4) regulate genes involved in amino acid synthesis, transport, and tRNA charging.</title><p>(<bold>A</bold>) Row-normalized heatmaps of NanoString gene expression data are shown from (1) serum-deprived wild-type (WT) or <italic>Tsc2</italic><sup>-/-</sup>mouse embryo fibroblasts (MEFs) treated (16 hr) with vehicle (Veh) or rapamycin (20 nM, Rap) (n = 2), (2) serum-deprived WT MEFs treated with insulin (500 nM, 16 hr, Ins) following 30 min pretreatment with vehicle or rapamycin (20 nM) (n = 2), and (3) WT and <italic>Tsc2<sup>-/-</sup></italic> MEFs transfected with <italic>Atf4</italic> siRNAs or non-targeting controls (siCT) and serum-deprived for 16 hr (n = 3). Genes are grouped by functional category and ranked in order of most significantly decreased with ATF4 knockdown for each group. Heatmap values are provided in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>, and effects on ATF4 protein levels and mTORC1 signaling for each condition are shown by immunoblot in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>. (<bold>B, C</bold>) qPCR analysis of the indicated transcripts in WT and <italic>Tsc2</italic><sup>-/-</sup> MEFs (<bold>B</bold>) or WT MEFs stimulated with insulin in the presence or absence of rapamycin (<bold>C</bold>) as in (<bold>A</bold>). Expression relative to vehicle-treated, unstimulated WT cells is graphed as mean ± SEM from three independent experiments, each with three biological replicates (n = 9). Effects of ATF4 knockdown are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>. (<bold>D, E</bold>) Representative immunoblots of <italic>Tsc2<sup>-/-</sup></italic> MEFs treated with vehicle or rapamycin as in (<bold>A</bold>) or serum-deprived WT MEFs stimulated with insulin (500 nM, 24 hr) following 30 min pretreatment with vehicle or rapamycin (20 nM), with biological duplicates shown for each condition. Quantification provided in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C, D</xref>. (<bold>F</bold>) Row-normalized heatmaps of NanoString gene expression data for transcripts in the functional groups from (<bold>A</bold>) found to be significantly (p&lt;0.05) induced in <italic>eIF2α<sup>A/A</sup></italic> MEFs treated with insulin (500 nM, 16 hr) following 30 min pretreatment with vehicle or rapamycin (20 nM) (n = 2). Genes are ranked by category in order of most significantly increased with insulin for each group. The heatmap values are provided in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>. Immunoblots validating that these cells are defective in the integrated stress response and qPCR validation of representative genes are provided in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E, F</xref>. (<bold>G</bold>) Representative immunoblot of cells treated as in (<bold>F</bold>), with biological duplicates shown for each condition. (<bold>H</bold>) Representative immunoblot of <italic>eIF2α<sup>A/A</sup></italic> MEFs transfected with siRNAs targeting <italic>Atf4, Tsc2,</italic> or non-targeting controls (CT) prior to serum starvation for 16 hr. (<bold>I, J</bold>) Representative immunoblot of serum-deprived LNCaP cells treated with vehicle or rapamycin (20 nM, 16 hr) (<bold>I</bold>) or <italic>Atf4</italic> siRNAs versus non-targeting controls (siCT) (<bold>J</bold>), with biological duplicates shown for each. (<bold>K, L</bold>) qPCR analysis of the indicated transcripts in LNCaP cells serum-starved in the presence of vehicle or rapamycin (20 nM, 16 hr) (<bold>K</bold>) or transfected with <italic>ATF4</italic> siRNAs or non-targeting controls (siCT) and serum-starved for 16 hr (<bold>L</bold>). Expression relative to vehicle-treated cells is graphed as mean ± SEM from two independent experiments, with three biological replicates each (n = 6). Immunoblots and qPCR analysis for PC3 cells treated as in (<bold>I–L</bold>) are provided in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G–J</xref>, and effects of c-Myc knockdown on representative gene targets are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1K, L</xref>. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant. One-way analysis of variance with Holm–Sidak method for multiple comparisons was used to determine statistical significance for (<bold>B, C</bold>). Unpaired two-tailed <italic>t</italic>-test was used to determine statistical significance for (<bold>F, K, L</bold>). (<bold>D, E, G, H, I, J</bold>) are representative of at least two independent experiments.</p><p> <supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Nanonstring data supporting <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-63326-fig3-data1-v2.xlsx"/></supplementary-material> </p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Supplmental data supporting <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title><p>(<bold>A</bold>) Representative immunoblots corresponding to NanoString heatmaps depicted in <xref ref-type="fig" rid="fig3">Figure 3A</xref>, with biological duplicates shown. (<bold>B</bold>) qPCR analysis of the indicated transcripts in <italic>Tsc2</italic><sup>-/-</sup>mouse embryo fibroblasts (MEFs) transfected with siRNAs as described in <xref ref-type="fig" rid="fig3">Figure 3A</xref>. Expression relative to non-targeting control (siCT) is graphed as mean ± SEM from three independent experiments, each with three biological replicates (n = 9). (<bold>C, D</bold>) Quantification of immunoblots shown in <xref ref-type="fig" rid="fig3">Figure 3D, E</xref>. (<bold>E</bold>) Representative immunoblot of <italic>eIF2α<sup>A/A</sup></italic> MEFs treated with vehicle or tunicamycin (2 µg/mL, 4 hr). (<bold>F</bold>) qPCR analysis of the indicated transcripts in eIF2<italic>α<sup>A/A</sup></italic> MEFs treated as described in <xref ref-type="fig" rid="fig3">Figure 3F</xref>. Expression relative to vehicle-treated, unstimulated cells is graphed as mean ± SEM from three independent experiments, each with three biological replicates (n = 9). (<bold>G, H</bold>) Representative immunoblots of serum-deprived PC3 cells treated with vehicle or rapamycin (20 nM, 16 hr) (<bold>G</bold>) or transfected with <italic>Atf4</italic> siRNAs or non-targeting controls (siCT) prior to serum deprivation (16 hr) (<bold>H</bold>), with biological duplicates for each condition shown. (<bold>I, J</bold>) qPCR analysis of the indicated transcripts in cells treated as described in (<bold>G, H</bold>). (<bold>K</bold>) Representative immunoblots of <italic>Tsc2<sup>-/-</sup></italic> MEFs transfected with control siRNAs (siCT) or those targeting <italic>Atf4</italic> or <italic>c-Myc</italic> prior to 16 hr serum deprivation. (<bold>L</bold>) qPCR analysis of the indicated transcripts in cells transfected as described in (<bold>K</bold>). Expression relative to siCT transfected cells is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). (<bold>A, E, G, H, K</bold>) are representative of at least two independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, calculated in (<bold>B, D, F, L</bold>) via one-way analysis of variance with Holm–Sidak method for multiple comparisons and (<bold>C, I, J</bold>) via unpaired two-tailed <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig3-figsupp1-v2.tif"/></fig></fig-group><p>The transcription factor c-MYC can be activated downstream of mTORC1 in some settings and has previously been shown to regulate many of the same ATF4 target genes encoding the enzymes of amino acid synthesis and transport, as well as aminoacyl tRNA synthetases (<xref ref-type="bibr" rid="bib11">Csibi et al., 2014</xref>; <xref ref-type="bibr" rid="bib59">Stine et al., 2015</xref>; <xref ref-type="bibr" rid="bib68">Wall et al., 2008</xref>; <xref ref-type="bibr" rid="bib82">Zirin et al., 2019</xref>). A survey of expression for 11 of such genes in <italic>Tsc2<sup>-/-</sup></italic> cells finds that the majority are not significantly affected by siRNA-mediated knockdown of c-MYC, whereas a few others are modestly but significantly decreased (e.g., <italic>Gars</italic>, <italic>Slc1a5</italic>, <italic>Psat1</italic>), albeit to a lesser degree than with siRNA-mediated knockdown of ATF4 (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1K, L</xref>).</p><p>To determine whether ATF4 activation is both necessary and sufficient for mTORC1-mediated regulation of these gene targets related to amino acid acquisition and utilization, we knocked out <italic>Atf4</italic> using CRISPR/Cas9 in <italic>Tsc2<sup>-/-</sup></italic> MEFs and confirmed biallelic disruption (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Protein levels of identified ATF4 targets were decreased in <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs and fully rescued with expression of wild-type ATF4 but not a DNA-binding domain mutant (ATF4<sup>DBD</sup>) (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). As mTORC1 regulates ATF4 translation through a mechanism requiring its 5′-UTR (<xref ref-type="bibr" rid="bib4">Ben-Sahra et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Park et al., 2017</xref>), the stably rescued cell lines, which express an ATF4 cDNA lacking the 5′-UTR, exhibit protein expression of ATF4 and its encoded gene targets that are resistant to rapamycin (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). The expression of select ATF4 target transcripts was markedly decreased in <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs to a similar extent to that measured in <italic>Atf4</italic> wild-type cells treated with rapamycin (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These transcript levels were rescued with the expression of wild-type ATF4, but not ATF4<sup>DBD</sup>, in a manner that was completely or partially rapamycin resistant (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These collective data show that mTORC1 signaling drives the expression of genes involved in tRNA export and charging, amino acid uptake, and NEAA synthesis through its downstream regulation of the ATF4 transcription factor.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Use of activating transcription factor 4 (ATF4) knockout cells and a rapamycin-resistant ATF4 to validate ATF4 targets regulated by mechanistic target of rapamycin complex 1 signaling.</title><p>(<bold>A</bold>) Schematic of ATF4 transcript, including upstream open reading frames (uORFs), coding sequence (CDS), and DNA-binding domain (DNABD), highlighting location of CRISPRn guides biallelic location of ATF4 mutations generated in <italic>Tsc2<sup>-/-</sup></italic> mouse embryo fibroblasts (MEFs). (<bold>B, C</bold>) Representative immunoblots of serum-deprived <italic>Tsc2<sup>-/-</sup></italic> (wild-type [WT]) MEFs or <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP, ATF4 lacking its 5′-UTR, or a DNABD mutant (DBD) of this ATF4 left untreated (<bold>B</bold>) or treated with vehicle or rapamycin (20 nM, 16 hr) (<bold>C</bold>), with biological duplicates shown for each condition. Immunoblots of proteins encoded by ATF4 gene targets in these cells are provided in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>. (<bold>D</bold>) qPCR analysis of the indicated transcripts from cells treated as in (<bold>C</bold>). Expression relative to WT vehicle-treated cells is graphed as the log<sub>2</sub> mean ± SD from a representative experiment with three biological replicates (n = 3). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, calculated via one-way analysis of variance with Holm–Sidak method for multiple comparisons. (<bold>B–D</bold>) are representative of at least two independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Supplemental data supporting <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>Representative immunoblots of serum-deprived <italic>Tsc2<sup>-/-</sup></italic> mouse embryo fibroblasts (MEFs) (<italic>Atf4</italic> wild-type) and <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP, activating transcription factor 4 (ATF4) lacking its 5′-UTR, or a DNABD mutant (DBD) of this ATF4 treated with vehicle or rapamycin (20 nM, 16 hr), with biological duplicates for each condition shown.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig4-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-3"><title>Activation of ATF4 contributes to the induction of protein synthesis downstream of mTORC1</title><p>mTORC1 induces protein synthesis through multiple downstream targets (<xref ref-type="bibr" rid="bib66">Valvezan and Manning, 2019</xref>). Given that the major mTORC1-regulated ATF4 target genes identified above are involved in amino acid uptake, synthesis, and tRNA charging, we hypothesized that ATF4 induction through mTORC1 signaling might contribute to the canonical increase in protein synthesis upon mTORC1 activation. Relative rates of protein synthesis were measured via [<sup>35</sup>S]-methionine incorporation into newly synthesized proteins in <italic>Tsc2<sup>+/+</sup></italic> and <italic>Tsc2<sup>-/-</sup></italic> cells treated with control siRNAs or <italic>Tsc2<sup>-/-</sup></italic> cells treated with siRNAs targeting ATF4 or Rheb, the small GTPase target of TSC2 that is an essential upstream activator of mTORC1. siRNA-mediated knockdown of either ATF4 or Rheb substantially decreased ATF4 protein levels in <italic>Tsc2<sup>-/-</sup></italic> cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Importantly, the elevated rate of protein synthesis in <italic>Tsc2<sup>-/-</sup></italic> MEFs was decreased with ATF4 knockdown to a similar extent to that observed with Rheb knockdown (<xref ref-type="fig" rid="fig5">Figure 5A, B</xref>). No change in mTORC1 signaling or phosphorylation of eIF2α was observed with ATF4 knockdown in this setting (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Protein synthesis was also measured in the <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> cell lines described above. Notably, the cells lacking ATF4 exhibited increased uptake of [<sup>35</sup>S]-methionine relative to parental cells and those reconstituted with ATF4 (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Despite this unexplained difference in methionine uptake, <italic>Atf4</italic> knockout cells exhibited a reduced rate of protein synthesis that was similar to the parental lines treated with rapamycin (<xref ref-type="fig" rid="fig5">Figure 5C, D</xref>). However, rapamycin treatment further reduced protein synthesis in the <italic>Atf4</italic> knockout cells. Importantly, cells reconstituted with the rapamycin-resistant ATF4 cDNA exhibited rescued protein synthesis, surpassing that observed in cells with endogenous ATF4, but this enhanced protein synthesis was still significantly reduced with rapamycin. Like <italic>Tsc2<sup>-/-</sup></italic> cells, wild-type cells cultured in the presence of growth factors exhibited reduced protein synthesis upon deletion of <italic>Atf4</italic>, again with a reduction similar to that from rapamycin treatment (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C, D</xref>). Together, these data suggest that ATF4 induction downstream of mTORC1 is necessary but not sufficient for mTORC1-regulated protein synthesis, consistent with the multiple mechanisms through which mTORC1 controls this key anabolic process.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Activation of activating transcription factor 4 (ATF4) contributes to the induction of protein synthesis downstream of mechanistic target of rapamycin complex 1.</title><p>(<bold>A, B</bold>) Representative autoradiogram and immunoblot of wild-type (WT) and <italic>Tsc2<sup>-/-</sup></italic> mouse embryo fibroblasts (MEFs) transfected with siRNAs targeting <italic>Atf4</italic> or <italic>Rheb1</italic> and <italic>Rhebl1</italic> or non-targeting controls (siCT) and serum-deprived for 16 hr with a pulse label of [<sup>35</sup>S]-methionine for the final 20 min (<bold>A</bold>) and quantified in (<bold>B</bold>). Biological triplicates from a representative experiment are shown in (<bold>A</bold>). (<bold>B</bold>) is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). Lack of effect of ATF4 knockdown on eIF2α phosphorylation is shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>. (<bold>C, D</bold>) Representative autoradiogram and immunoblot of serum-deprived <italic>Tsc2<sup>-/-</sup></italic> MEFs (WT) or <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP or ATF4 lacking its 5′-UTR treated with vehicle or rapamycin (20 nM, 16 hr) with a pulse label of [<sup>35</sup>S]-methionine for the final 20 min (<bold>C</bold>) and quantified in (<bold>D</bold>). Biological triplicates from a representative experiment are shown in (<bold>C</bold>). (<bold>D</bold>) is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). Measurement of methionine uptake in these cells is provided in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>, and effects of ATF4 knockout on protein synthesis in growth factor-stimulated WT MEFs are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C, D</xref>. (<bold>B,D</bold>) *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, calculated via one-way analysis of variance with Holm–Sidak method for multiple comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Supplemental data supporting <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title><p>(<bold>A</bold>) Representative immunoblots of <italic>Tsc2<sup>-/-</sup></italic> mouse embryo fibroblasts (MEFs) transfected with <italic>Atf4, Rheb</italic>, or non-targeting control (siCT) siRNAs prior to serum starvation for 16 hr, with biological duplicates shown. Data is representative of at least three independent experiments. (<bold>B</bold>) Cellular methionine uptake in serum-deprived <italic>Tsc2<sup>-/-</sup></italic> MEFs (<italic>Atf4</italic> wild-type [WT]) and<italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP or activating transcription factor 4 was assayed and graphed as mean ± SEM relative to WT cells with data from two independent experiments, with three biological replicates each (n = 6). (<bold>C, D</bold>) Representative autoradiogram and immunoblots of protein extracts from <italic>Atf4<sup>+/+</sup></italic> and <italic>Atf4<sup>-/-</sup></italic> MEFs grown in the presence of serum and treated with vehicle (Veh) or rapamycin (20 nM, Rap, 16 hr) and pulse labeled with [<sup>35</sup>S]-methionine for the final 20 min, with biological duplicates from a representative experiment shown (<bold>C</bold>) and autoradiograms quantified and graphed as mean ± SEM from two independent experiments, each with two biological replicates (n = 4) (<bold>D</bold>). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.0001, ns = not significant, calculated for (<bold>B, D</bold>) via one-way analysis of variance with Holm–Sidak method for multiple comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>mTORC1 regulates cystine uptake through ATF4</title><p>Among the 61 shared mTORC1- and ISR-induced ATF4 gene targets identified, the cystine-glutamate antiporter <italic>Slc7a11</italic> was the gene with the highest fold induction by RNA-seq analysis upon insulin treatment (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). SLC7A11 (also known as xCT) associates with SLC3A2 (CD98) at the plasma membrane and serves as the primary transporter of cystine, the oxidized form of cysteine and predominant cysteine species in both plasma and cell culture media, whereas reduced cysteine is transported through neutral amino acid systems (<xref ref-type="fig" rid="fig6">Figure 6A</xref>; <xref ref-type="bibr" rid="bib3">Bannai and Kitamura, 1980</xref>; <xref ref-type="bibr" rid="bib10">Conrad and Sato, 2012</xref>). Transcript levels of <italic>Slc7a11</italic> were sensitive to rapamycin in <italic>Tsc2<sup>-/-</sup></italic> MEFs and greatly decreased with ATF4 knockout (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Upon reconstitution with rapamycin-resistant ATF4, expression of <italic>Slc7a11</italic> was rescued and no longer sensitive to rapamycin, while the ATF4<sup>DBD</sup> mutant was unable to restore <italic>Slc7a11</italic> transcript levels. A similar pattern of mTORC1- and ATF4-regulated expression was measured for <italic>Slc3a2</italic> (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). SLC7A11 protein, detected using an antibody validated with siRNA knockdown (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), decreased in <italic>Tsc2<sup>-/-</sup></italic> MEFs treated with mTOR inhibitors and were increased in wild-type MEFs stimulated with insulin in an mTOR-dependent manner (<xref ref-type="fig" rid="fig6">Figure 6D, E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B, C</xref>). <italic>SLC7A11</italic> transcript levels were also decreased with both ATF4 knockdown and rapamycin in the PTEN-deficient cancer cell lines LNCaP and PC3, although <italic>SLC7A11</italic> expression was relatively more resistant to rapamycin in PC3 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D, E</xref>). SLC7A11 protein levels likewise decreased in LNCaP and PC3 cells treated with mTOR inhibitors, without significant changes to the <italic>SLC3A2</italic> gene product CD98 (<xref ref-type="fig" rid="fig6">Figure 6F</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F–H</xref>). These data confirm and extend the findings from RNA-seq and NanoString analyses (<xref ref-type="fig" rid="fig1">Figure 1F</xref>, <xref ref-type="fig" rid="fig3">Figure 3A, F</xref>) and demonstrate that ATF4 is both necessary and sufficient for the mTORC1-mediated induction of <italic>Slc7a11</italic> expression.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Mechanistic target of rapamycin complex 1 (mTORC1) regulates cystine uptake through activating transcription factor 4 (ATF4) and its target SLC7A11.</title><p>(<bold>A</bold>) Schematic of transporter xCT, encoded by <italic>Slc7a11</italic>, which heterodimerizes with SLC3A2 to serve as a cystine (Cys<sub>2</sub>)/glutamate anti-porter. Cystine is reduced to cysteine (Cys), which is essential for glutathione synthesis. Cysteine transport is mediated by neutral amino acid trasporters distinct from xCT. The targets of erastin and buthionine-sulfoximine, two compounds used in this study, are also depicted. (<bold>B, C</bold>) qPCR analysis of <italic>Slc7a11</italic> (<bold>B</bold>) or <italic>Slc3a2</italic> (<bold>C</bold>) in serum-deprived <italic>Tsc2<sup>-/-</sup></italic> mouse embryo fibroblasts (MEFs) (wild-type [WT]) and <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP (control), ATF4 lacking its 5′-UTR, or a DNABD mutant (DBD) of this ATF4 treated with vehicle or rapamycin (20 nM, 16 hr). Expression relative to WT vehicle-treated cells is graphed as the log<sub>2</sub> mean ± SD from a representative experiment with three biological replicates (n = 3). (<bold>D–F</bold>) Representative immunoblots of serum-deprived <italic>Tsc2<sup>-/-</sup></italic> MEFs (<bold>D</bold>), insulin-stimulated (500 nM, 24 hr) WT MEFs (<bold>E</bold>), or serum-deprived LNCaP cells (<bold>F</bold>) treated 24 hr (<bold>D, E</bold>) or 16 hr (<bold>F</bold>) with vehicle, rapamycin (20 nM), or Torin1 (250 nM), shown with biological duplicates. The SLC7A11 antibody is validated for use in MEFs in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, corresponding immunoblots quantified in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B, C, F</xref>. Effects of ATF4 knockdown and rapamycin on <italic>SLC7A11</italic> transcripts in LNCaP and PC3 cells are shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D, E</xref>, and corresponding immunoblots and protein quantification are provided in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1G, H</xref>. (<bold>G, H</bold>) Representative growth curves of <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of GFP, ATF4, or ATF4<sup>DBD</sup> grown in 10% dialyzed fetal bovine serum (FBS) with Dulbecco’s Modified Eagle’s Medium (DMEM) (<bold>G</bold>) or DMEM supplemented with cysteine alone (Cys, 1 mM), nonessential amino acids (100 μM each) lacking cysteine (NEAA-Cys), or nonessential amino acids plus either cysteine (1 mM, NEAA+Cys), or cystine (0.5 mM, NEAA+Cys<sub>2</sub>) (<bold>H</bold>). Mean cell numbers ± SD relative to day 0 are graphed from three biological replicates (n = 3). (<bold>I</bold>) Cell death of <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP, ATF4, or SLC7A11 cultured in DMEM with 10% dialyzed FBS was quantified by annexin V and propidium iodide (PI) staining after 72 hr and graphed as the mean percentage of total cells ± SD from three biological replicates (n = 3). (<bold>J</bold>) Cystine uptake in serum-deprived <italic>Tsc2<sup>-/-</sup></italic> MEFs treated with vehicle, rapamycin (20 nM), or erastin (10 μM) for 16 hr is graphed as the mean ± SEM radiolabel incorporation from C<sup>14</sup>-cystine over the final 10 min relative to vehicle-treated cells from two independent experiments, with three biological replicates each (n = 6). The effect of mTOR inhibitors on cystine uptake in littermate-derived <italic>Rictor<sup>+/+</sup></italic> and <italic>Rictor<sup>-/-</sup></italic> MEFs, and corresponding immunoblots, is shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1I, J</xref>. (<bold>K</bold>) Cystine uptake in serum-deprived WT and <italic>Atf4<sup>-/-</sup></italic> MEFs pretreated 30 min with vehicle or rapamycin (20 nM) prior to insulin stimulation (500 nM, 24 hr) or treated with erastin (10 μM, 30 min) was assayed and graphed as in (<bold>J</bold>) relative to vehicle-treated WT cells with data from three independent experiments, with three biological replicates each (n = 9). (<bold>L</bold>) Cystine uptake in serum-deprived <italic>Tsc2<sup>-/-</sup></italic> MEFs (WT) and<italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP or ATF4 treated with vehicle or rapamycin (20 nM) for 16 hr was assayed and graphed as in (<bold>J</bold>) relative to vehicle-treated WT cells with data from two independent experiments, with three biological replicates each (n = 6). (<bold>B–I</bold>) are representative of at least two independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, calculated in (<bold>B, C, I, J, K, L</bold>) via one-way analysis of variance with Holm–Sidak method for multiple comparisons and in (<bold>G, H</bold>) via unpaired two-tailed <italic>t</italic>-test. For (<bold>I</bold>), the sum of annexin V+/PI-, annexin V-/PI+, and annexin V+/PI+ populations were used for comparisons to the annexin V-/P- population.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Supplemental data supporting <xref ref-type="fig" rid="fig6">Figure 6</xref>.</title><p>(<bold>A</bold>) Representative immunoblot of <italic>Tsc2<sup>-/-</sup></italic> mouse embryo fibroblasts (MEFs) transfected with <italic>Slc7a11</italic> or non-targeting control (siCT) siRNAs prior to serum starvation for 16 hr. (<bold>B, C</bold>) Quantification of representative immunoblots from <xref ref-type="fig" rid="fig6">Figure 6D, E</xref>. (<bold>D, E</bold>) qPCR analysis of <italic>SLC7A11</italic> transcripts in serum-deprived LNCaP (<bold>D</bold>) or PC3 (<bold>E</bold>) cells either transfected with siRNAs targeting <italic>ATF4</italic> or non-targeting controls (siCT) (left) or treated with vehicle or rapamycin (20 nM, 16 hr) (right). Expression relative to siCT or vehicle-treated cells is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). (<bold>F</bold>) Quantification of representative immunoblots shown in <xref ref-type="fig" rid="fig6">Figure 6F</xref>. (<bold>G, H</bold>) Representative immunoblot of serum-deprived PC3 cells treated (16 hr) with vehicle, rapamycin (20 nM), or Torin1 (250 nM), shown with biological duplicates (<bold>G</bold>) and quantified in (<bold>H</bold>). (<bold>I, J</bold>) Cystine uptake in <italic>Rictor<sup>+/+</sup></italic> and <italic>Rictor<sup>-/-</sup></italic> MEFs grown in full serum and treated with vehicle, rapamycin (20 nM, 24 hr), Torin1 (250 nM, 24 hr), or erastin (10 μM, 30 min) was assayed and graphed as in <xref ref-type="fig" rid="fig6">Figure 6J</xref> relative to vehicle-treated <italic>Rictor<sup>+/+</sup></italic> cells with data from two independent experiments, with three biological replicates each (n = 6). Representative immunoblots shown in (<bold>J</bold>). (<bold>A, G, J</bold>) are representative of two independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, calculated for (<bold>D, E</bold>) via unpaired two-tailed <italic>t</italic>-test and (<bold>B, C, F, H, I</bold>) via one-way analysis of variance with Holm–Sidak method for multiple comparisons.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig6-figsupp1-v2.tif"/></fig></fig-group><p>ATF4 is known to be important for the uptake and synthesis of NEAAs (<xref ref-type="bibr" rid="bib21">Harding et al., 2003</xref>). In agreement with this, we observed that <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> cells fail to proliferate in Dulbecco’s Modified Eagle’s Medium (DMEM), which only contains a subset of NEAAs, while addback of wild-type ATF4, but not ATF4<sup>DBD</sup>, restored proliferation (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Supplementation of DMEM with a mixture of all NEAAs, including cysteine, allowed the <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs to proliferate at the same rate as the ATF4-reconstituted cells, while NEAAs lacking cysteine completely failed to support proliferation of these cells (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Furthermore, supplementation with excess reduced cysteine alone, but not equimolar concentrations of oxidized cysteine in the form of cystine, was able to significantly increase proliferation of the <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs, albeit to a lesser extent than NEAAs plus cysteine. The majority of these cells die after 72 hr in DMEM, and exogenous expression of either ATF4 or SLC7A11 restores their survival (<xref ref-type="fig" rid="fig6">Figure 6I</xref>). Taken together, these data indicate that a defect in the acquisition of cysteine, which normally occurs through SLC7A11-mediated uptake of cystine, underlies the inability of <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> cells to proliferate or survive in DMEM and suggest a key role for mTORC1 signaling in controlling cystine uptake through ATF4.</p><p>To directly test whether mTORC1 influences cystine uptake, we employed both genetic (<italic>Tsc2</italic> loss) and physiological (insulin stimulation) activation of mTORC1, measuring [<sup>14</sup>C]-cystine uptake in the presence or absence of rapamycin or the xCT inhibitor erastin (<xref ref-type="fig" rid="fig6">Figure 6A</xref>; <xref ref-type="bibr" rid="bib75">Yang and Stockwell, 2008</xref>). Both rapamycin and erastin significantly decreased [<sup>14</sup>C]-cystine uptake into <italic>Tsc2<sup>-/-</sup></italic> MEFs (<xref ref-type="fig" rid="fig6">Figure 6J</xref>). In wild-type MEFs, insulin stimulated an increase in cystine uptake that was inhibited with rapamycin, and this mTORC1-regulated cystine transport was completely lost with ATF4 knockout, reduced to levels of erastin-treated cells (<xref ref-type="fig" rid="fig6">Figure 6K</xref>). Additionally, <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs showed a decrease in cystine uptake when compared to parental <italic>Tsc2<sup>-/-</sup></italic> MEFs, which could be rescued with re-expression of ATF4 (<xref ref-type="fig" rid="fig6">Figure 6L</xref>). However, cystine consumption in cells reconstituted with rapamycin-resistant ATF4 was still significantly sensitive to rapamycin treatment, suggesting the existence of additional, ATF4-independent mechanisms influencing the transport or cellular incorporation of cystine downstream of mTORC1. As mTORC2 has been previously suggested to directly regulate xCT (<xref ref-type="bibr" rid="bib17">Gu et al., 2017</xref>), we utilized <italic>Rictor<sup>-/-</sup></italic> MEFs, which lack mTORC2 activity, to determine whether mTORC2 was contributing to the decreased cystine uptake observed upon treatment with mTOR inhibitors. While <italic>Rictor<sup>-/-</sup></italic> MEFs displayed increased uptake of cystine relative to their wild-type counterparts, cystine uptake, as well as ATF4 protein levels, was sensitive to rapamycin and Torin1 in both cell lines (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1I, J</xref>). Thus, mTORC1 promotes cellular cystine uptake, at least in part, through the activation of ATF4 and induction of <italic>Slc7a11</italic> expression, which supports cell proliferation and survival.</p></sec><sec id="s2-5"><title>mTORC1 regulates glutathione levels through ATF4-mediated induction of <italic>Slc7a11</italic></title><p>Cysteine, generally acquired through cystine uptake and reduction, is an essential component of the tripeptide glutathione (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), the most abundant antioxidant in cells (<xref ref-type="bibr" rid="bib42">Meister, 1983</xref>). We hypothesized that the regulation of cystine uptake through mTORC1 and ATF4 might influence cellular glutathione content. Indeed, mTORC1 inhibition with rapamycin or Torin1 significantly decreased total glutathione levels in <italic>Tsc2<sup>-/-</sup></italic> MEFs, albeit less than buthionine-sulfoximine (BSO), a direct inhibitor of glutathione synthesis (<xref ref-type="fig" rid="fig7">Figure 7A</xref>; <xref ref-type="bibr" rid="bib16">Griffith and Meister, 1979</xref>). Similar to BSO treatment, mTOR inhibitors decreased both reduced (GSH) and oxidized (GSSG) forms of glutathione to the same degree, indicating effects on total glutathione abundance rather than its redox state (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>). Stable reconstitution of <italic>Tsc2<sup>-/-</sup></italic> MEFs with TSC2 also decreased total glutathione levels (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). To examine this response in vivo, we employed a mouse model of tuberous sclerosis complex involving xenograft tumors derived from the rat <italic>TSC2<sup>-/-</sup></italic> tumor cell line ELT3 (<xref ref-type="bibr" rid="bib24">Hodges et al., 2002</xref>). To avoid major differences in tumor size from the treatments, we treated tumor-bearing mice for just 5 days with either vehicle or rapamycin, prior to harvesting tumors for immunoblot analysis and metabolite profiling. Importantly, we found that rapamycin treatment strongly decreased ATF4 protein levels in these tumors with a concomitant decrease in glutathione levels, measured by LC-MS in tumor metabolite extracts (<xref ref-type="fig" rid="fig7">Figure 7C, D</xref>). An analysis of published metabolomics data (<xref ref-type="bibr" rid="bib61">Tang et al., 2019</xref>) also revealed that rapamycin treatment significantly decreased glutathione levels in human TSC2-deficient angiomyolipoma cells (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>). Likewise, inhibition of mTORC1 signaling with rapamycin or Torin1 in LNCaP and PC3 cells resulted in a significant decrease in total glutathione levels, although the degree of decrease varied between the two cell lines (<xref ref-type="fig" rid="fig7">Figure 7E</xref>), perhaps reflecting the above finding that SLC7A11 expression is more resistant to mTOR inhibitors in PC3 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D–H</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mechanistic target of rapamycin complex 1 (mTORC1) regulates cellular glutathione levels through activating transcription factor 4 (ATF4) and SLC7A11-mediated cystine uptake.</title><p>(<bold>A</bold>) Total glutathione in serum-deprived <italic>Tsc2</italic><sup>-/-</sup>mouse embryo fibroblasts (MEFs) treated with rapamycin (20 nM), Torin1 (250 nM), or buthionine-sulfoximine (BSO) (10 μM) for 16 hr is graphed as mean ± SEM relative to vehicle-treated cells from three independent experiments, each with three biological replicates (n = 9). Relative abundance of reduced (GSH) and oxidized (GSSG) glutathione from this experiment is shown in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A</xref>. (<bold>B</bold>) Relative total glutathione in serum-deprived <italic>Tsc2</italic><sup>-/-</sup> MEFs with stable reconstitution of a cDNA encoding TSC2 or empty vector (EV) control is graphed as mean ± SD from a representative experiment with three biological replicates (n = 3). (<bold>C, D</bold>) Immunoblot (<bold>C</bold>) and relative glutathione levels measured by LC-MS/MS (<bold>D</bold>) from <italic>Tsc2</italic><sup>-/-</sup> ELT3 xenograft tumors resected from mice treated for 5 days with vehicle or rapamycin (1 mg/kg on days 1, 3, and 5) (n = 3 mice/group). Relative glutathione levels from rapamycin-treated human <italic>TSC2<sup>-/-</sup></italic> tumor cells are shown in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1B</xref>. (<bold>E</bold>) Total glutathione in serum-deprived LNCaP (left) and PC3 (right) cells treated with vehicle, rapamycin (20 nM), Torin1 (250 nM), or BSO (50 μM) for 24 hr is graphed as mean ± SD relative to vehicle-treated cells from a representative experiment with three biological replicates (n = 3). (<bold>F</bold>) Total glutathione in serum-deprived <italic>Tsc2</italic><sup>-/-</sup> MEFs (<italic>Atf4</italic> wild-type [WT]) and <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP (control), ATF4, ATF4<sup>DBD</sup>, or SLC7A11 grown in Dulbecco’s Modified Eagle’s Medium and supplemented, where indicated, with cysteine (1 mM, Cys) or cystine (0.5 mM, Cys<sub>2</sub>) is graphed as mean ± SD relative to WT cells from a representative experiment with three biological replicates (n = 3). Relative glutathione in these cells supplemented with nonessential amino acid with or without Cys, measured by LC-MS/MS, is shown in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>. (<bold>G</bold>) Total glutathione in serum-deprived <italic>Atf4<sup>+/+</sup></italic> and <italic>Atf4<sup>-/-</sup></italic> MEFs pretreated 30 min with vehicle or rapamycin (20 nM) prior to insulin stimulation (500 nM, 24 hr) or treated with BSO (10 μM, 24 hr) is graphed as mean ± SEM relative to unstimulated Atf4<sup>+/+</sup> cells from two independent experiments, with three biological replicates each (n = 6). (<bold>H</bold>) Total glutathione in serum-deprived <italic>Tsc2</italic><sup>-/-</sup> MEFs (<italic>Atf4</italic> WT) and <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with stable expression of cDNAs encoding GFP, ATF4 lacking its 5′-UTR, or a DNABD mutant (DBD) of this ATF4 treated with vehicle or rapamycin (20 nM) for 16 hr is graphed as mean ± SD relative to vehicle-treated WT cells from a representative experiment with three biological replicates (n = 3). Effects of mTORC1 signaling and ATF4 on GCLC and GCLM transcript and protein levels are shown in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D–G</xref>. (<bold>B, E, F, H</bold>) are representative of at least two independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant, calculated in (<bold>A, E, F, G, H</bold>) via one-way analysis of variance with Holm–Sidak method for multiple comparisons and in (<bold>B, D</bold>) via unpaired two-tailed <italic>t</italic>-test.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Supplemental data supporting <xref ref-type="fig" rid="fig7">Figure 7</xref>.</title><p>(<bold>A</bold>) Relative GSH and GSSG levels in serum-deprived <italic>Tsc2</italic><sup>-/-</sup>mouse embryo fibroblasts (MEFs) treated with rapamycin (20 nM,16 h), Torin1 (250 nM, 16 hr), or buthionine-sulfoximine (10 μM, 16 hr). GSH and GSSG levels relative to vehicle-treated cells are graphed as mean ± SEM from three independent experiments, with three biological replicates each (n = 9). (<bold>B</bold>) Total glutathione levels in human <italic>TSC2<sup>-/-</sup></italic> angiomyolipoma cells treated with vehicle or rapamycin (20 nM, 24 hr) measured by LC-MS/MS (mean ± SD, n = 3). (<bold>C</bold>) Normalized peak area of reduced glutathione from LC-MS/MS analysis of serum-deprived <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs with addback of GFP or activating transcription factor 4 (ATF4) in the presence of supplemented cysteine (1 mM), nonessential amino acids without cysteine (100 µM each), or nonessential amino acids (1 mM cysteine or 100 µM) (mean ± SD, n = 3). (<bold>D, E</bold>) Transcript abundance of <italic>Gclc</italic> and <italic>Gclm</italic> in serum-deprived <italic>Tsc2</italic><sup>-/-</sup> MEFs treated with vehicle or rapamycin (20 nM, 16 hr) (<bold>D</bold>) or transfected with siRNAs targeting <italic>Atf4</italic> or non-targeting controls (siCT) (<bold>E</bold>). Expression relative to vehicle (<bold>D</bold>) or siCT(E) is graphed as mean ± SEM from two independent experiments, each with three biological replicates (n = 6). (<bold>F, G</bold>) Representative immunoblots of cells treated as in <xref ref-type="fig" rid="fig7">Figure 7G, H</xref>, except where indicated in (<bold>F</bold>), cells were treated with Torin1 (250 nM), with biological duplicates provided for each condition. (<bold>C, F, G</bold>) are representative of two independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ns = not significant calculated for (<bold>A, C</bold>) via one-way analysis of variance with Holm–Sidak method for multiple comparisons and unpaired two-tailed <italic>t</italic>-test for (<bold>B, D, E</bold>).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-63326-fig7-figsupp1-v2.tif"/></fig></fig-group><p>To determine the role of ATF4 and SLC7A11-dependent cystine uptake in glutathione synthesis downstream of mTORC1 signaling, we compared <italic>Tsc2<sup>-/-</sup></italic> MEFs with or without <italic>Atf4</italic> knockout. Total glutathione levels were greatly decreased in <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs, and exogenous expression of ATF4 or SLC7A11, but not ATF4<sup>DBD</sup>, was able to restore glutathione levels to these cells (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Supplementation with all NEAAs or just cysteine, transported through neutral amino acid systems, but not equimolar concentrations of cystine, transported through SLC7A11, also rescued total glutathione levels, as measured by either enzymatic assay or LC-MS (<xref ref-type="fig" rid="fig7">Figure 7F</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>). Furthermore, insulin stimulated an increase in glutathione levels in wild-type MEFs in a manner completely sensitive to rapamycin, an effect ablated in <italic>Atf4</italic> knockout cells, which had a very low abundance of glutathione (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). Likewise, the rapamycin-sensitive nature of glutathione in <italic>Tsc2<sup>-/-</sup></italic> MEFs was completely lost in <italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> MEFs (<xref ref-type="fig" rid="fig7">Figure 7H</xref>). Glutathione levels were restored to these cells upon exogenous expression of ATF4, but not the ATF4<sup>DBD</sup> mutant. However, glutathione was still significantly reduced with rapamycin treatment in cells expressing the rapamycin-resistant ATF4, suggesting possible ATF4-independent mechanisms also contributing to this regulation (<xref ref-type="bibr" rid="bib33">Lam et al., 2017</xref>). As one possible contributing factor, we found that the transcript encoding both the catalytic (GCLC) and regulatory (GCLM) subunits of glutamate-cysteine ligase, the first enzyme of glutathione synthesis, was sensitive rapamycin, in a manner unaffected by ATF4 knockdown (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D, E</xref>). We also found that GCLC and GCLM protein levels could be modestly induced by insulin through mTORC1 signaling in both wild-type and ATF4 knockout cells, but their protein abundance was unaffected by rapamycin in <italic>Tsc2<sup>-/-</sup></italic> MEFs (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1F, G</xref>). Thus, the mechanism underlying the apparent ATF4-independent effects of mTORC1 signaling on glutathione levels remains unknown. These collective data show that mTORC1 signaling induces glutathione synthesis, at least in part, through the activation of ATF4 and SLC7A11-dependent cystine uptake.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our findings expand the functional repertoire of mTORC1 signaling as it relates to the control of anabolic processes and cellular metabolism through its noncanonical activation of ATF4. Importantly, less than 10% of stress-responsive, ATF4-dependent targets were found to be significantly stimulated through the mTORC1-mediated activation of ATF4 in response to insulin. Among others, we found that genes involved in amino acid biosynthesis, transport, and tRNA charging were induced by mTORC1-ATF4 signaling, many to a comparable level to that of ER-stress induction with tunicamycin. While the molecular nature of this selective induction remains unknown, our data suggest that the 61 ATF4-dependent genes shared in their induction between mTORC1 signaling and the ISR represent targets most highly responsive to increases in ATF4 levels. Since mTORC1 signaling leads to a more modest increase in ATF4 protein levels than does the ISR, the selective induction of these genes might be reminiscent of the dose-dependent activation of MYC target genes documented in other studies (<xref ref-type="bibr" rid="bib55">Sabò et al., 2014</xref>; <xref ref-type="bibr" rid="bib58">Schuhmacher and Eick, 2013</xref>; <xref ref-type="bibr" rid="bib70">Walz et al., 2014</xref>). Our bioinformatic analyses and functional data also indicate involvement of the C/EBP family of transcription factors as heterodimerization partners of ATF4 for the regulation of these gene targets shared between mTORC1 signaling and the ISR.</p><p>Consistent with the specific ATF4 target genes induced by mTORC1 signaling, including those involved in amino acid acquisition and tRNA charging, we found that ATF4 activation contributes to both canonical (e.g., protein synthesis) and new (e.g., glutathione synthesis) functions of mTORC1. As mTORC1 stimulates protein synthesis through multiple downstream targets (<xref ref-type="bibr" rid="bib25">Holz et al., 2005</xref>; <xref ref-type="bibr" rid="bib29">Jefferies et al., 1994</xref>; <xref ref-type="bibr" rid="bib40">Ma and Blenis, 2009</xref>; <xref ref-type="bibr" rid="bib51">Raught et al., 2004</xref>; <xref ref-type="bibr" rid="bib63">Thoreen et al., 2012</xref>), it was not surprising to find that ATF4 was necessary but not sufficient for the increased rate of protein synthesis accompanying mTORC1 activation. We also demonstrate that mTORC1 signaling regulates the abundance of total cellular glutathione, both reduced and oxidized, at least in part through the ATF4-dependent induction of the cystine transporter SLC7A11, a major source of the cysteine that is limiting for glutathione synthesis. Importantly, this mTORC1-ATF4-mediated transcriptional upregulation of SLC7A11 leading to increased cystine uptake would temporally follow the inhibition of SLC7A11 recently found to be mediated through mTORC2 and Akt-dependent transient phosphorylation of the transporter (<xref ref-type="bibr" rid="bib17">Gu et al., 2017</xref>; <xref ref-type="bibr" rid="bib39">Lien et al., 2017</xref>). Our findings are consistent with a recent study indicating rapamycin-sensitive expression of xCT in TSC models, which the authors attribute to the OCT1 transcription factor (<xref ref-type="bibr" rid="bib37">Li et al., 2019</xref>). However, our study indicates that the mTORC1-mediated activation of ATF4 is both necessary and sufficient for this regulation. The transcription factor NRF2 (also known as NFE2L2) is activated by oxidative stress and is a master regulator of the enzymes required for glutathione synthesis, as well as SLC7A11 to increase cystine uptake (<xref ref-type="bibr" rid="bib18">Habib et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Sasaki et al., 2002</xref>; <xref ref-type="bibr" rid="bib76">Ye et al., 2014</xref>). While NRF2 depletion has been described to decrease the viability of cells with TSC gene loss (<xref ref-type="bibr" rid="bib78">Zarei et al., 2019</xref>), we have no evidence from this or previous studies that mTORC1 signaling influences the levels or activity of NRF2 (<xref ref-type="bibr" rid="bib79">Zhang et al., 2014</xref>). mTORC1 serves to couple growth signals to the coordinated control of anabolic processes, including the biosynthesis of protein, lipids, and nucleotides, as well as metabolic pathways that support this anabolic state (<xref ref-type="bibr" rid="bib66">Valvezan and Manning, 2019</xref>). This metabolic program is orchestrated to provide biosynthetic precursors and directly promote the synthesis of macromolecules while also maintaining cellular homeostasis and preventing nutrient or metabolic stress. For example, mTORC1 signaling promotes metabolic flux through the NADPH-producing oxidative branch of the pentose phosphate pathway, thereby providing the reducing power essential to support an mTORC1-stimulated increase in de novo lipid synthesis (<xref ref-type="bibr" rid="bib13">Düvel et al., 2010</xref>). Importantly, NADPH is also essential to reduce cystine, taken up through SLC7A11, into two molecules of cysteine for use in glutathione synthesis, in addition to being required to regenerate reduced glutathione following its oxidation. Supporting this logic of a coordinated metabolic program downstream of mTORC1, pro-growth signaling through mTORC1 likely promotes glutathione synthesis to help buffer against the oxidative stress that accompanies anabolic metabolism and increased rates of protein synthesis (<xref ref-type="bibr" rid="bib19">Han et al., 2013</xref>; <xref ref-type="bibr" rid="bib21">Harding et al., 2003</xref>; <xref ref-type="bibr" rid="bib31">Kong and Chandel, 2018</xref>).</p><p>Our findings further support the addition of ATF4 to SREBP and HIF1, as nutrient- and stress-sensing transcription factors that are independently co-opted by mTORC1 signaling to drive the expression of metabolic enzymes and nutrient transporters. Unlike adaptive signals stemming from the depletion of individual nutrients, such as amino acids, sterols, or oxygen, which generally attenuate mTORC1 signaling as part of the adaptive response, pro-growth signals that activate mTORC1 can stimulate these transcription factors in concert to support a broader anabolic program. It will be important in future studies to understand the dual regulation of these transcription factors by both pro-growth and adaptive mechanisms as it relates to settings of physiological (fasting and feeding) and pathological (tumor development) nutrient fluctuations.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Biological sample (<italic>Mus musculus</italic>)</td><td valign="top">ELT3 tumor samples</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29056426">29056426</ext-link></td><td valign="top"/><td valign="top"><xref ref-type="bibr" rid="bib65">Valvezan et al., 2017</xref></td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top">WT and <italic>Tsc2<sup>-/-</sup></italic> MEFs</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/14561707">14561707</ext-link></td><td valign="top"/><td valign="top">David Kwiatkowski</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top"><italic>EIF2a<sup>A/A</sup></italic> MEFs</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/11430820">11430820</ext-link></td><td valign="top"/><td valign="top">Randal Kaufman</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top"><italic>Rictor<sup>+/+</sup></italic> and <italic>Rictor<sup>-/-</sup></italic> MEFs</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/17141160">17141160</ext-link></td><td valign="top"/><td valign="top">D.A. Guertin and D.M. Sabatini</td></tr><tr><td valign="top">Cell line (<italic>Homo sapiens</italic>)</td><td valign="top">PC3</td><td valign="top">ATCC</td><td valign="top">CRL-1435 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0035">CVCL_0035</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>H. sapiens</italic>)</td><td valign="top">LNCaP</td><td valign="top">ATCC</td><td valign="top">CRL-1740 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_1379">CVCL_1379</ext-link></td><td valign="top"/></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top"><italic>Tsc2<sup>+/+</sup> Atf4<sup>-/-</sup></italic> <break/>MEFs</td><td valign="top">This paper</td><td valign="top"/><td valign="top">CRISPR-Cas9n generated – see Materials and methods</td></tr><tr><td valign="top">Cell line (<italic>M. musculus</italic>)</td><td valign="top"><italic>Tsc2<sup>-/-</sup> Atf4<sup>-/-</sup></italic> <break/>MEFs</td><td valign="top">This paper</td><td valign="top"/><td valign="top">CRISPR-Cas9n generated – see Materials and methods</td></tr><tr><td valign="top">Transfected construct (<italic>Aequorea victoria</italic>)</td><td valign="top">pTRIPZ-EGFP</td><td valign="top">This paper</td><td valign="top"/><td valign="top">eGFP cDNA- expressing control plasmid – see Materials and methods</td></tr><tr><td valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td valign="top">pTRIPZ-ATF4</td><td valign="top">This paper</td><td valign="top"/><td valign="top">Rapamycin-resistant ATF4 cDNA-expressing plasmid – see Materials and methods</td></tr><tr><td valign="top">Transfected construct (<italic>M. musculus</italic>)</td><td valign="top">pTRIPZ-ATF4<sup>DBD</sup></td><td valign="top">This paper</td><td valign="top"/><td valign="top">ATF4 DNA-binding domain mutant cDNA-expressing plasmid – see Materials and methods</td></tr><tr><td valign="top">Transfected construct (<italic>H. sapiens</italic>)</td><td valign="top">pTRIPZ-SLC7A11</td><td valign="top">This paper</td><td valign="top"/><td valign="top">SLC7A11 cDNA-expressing plasmid – see Materials and methods</td></tr><tr><td valign="top">Transfected construct (human, mouse)</td><td valign="top">Non-targeting pool for siRNA experiments</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">D-001810-10-50</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siMyc</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-040813-00-0010</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siAtf4</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-042737-01-0020</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siRheb</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-057044-00-0020</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siRhebL1</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-056074-01-0020</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siTsc2</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-047050-00-0020</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siC/ebpα</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-040561-00-0005</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siC/ebpβ</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-043110-00-0005</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siC/ebpδ</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-060294-01-0005</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (mouse)</td><td valign="top">siC/ebpγ</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-065627-00-0005</td><td valign="top"/></tr><tr><td valign="top">Transfected construct (human)</td><td valign="top">siATF4</td><td valign="top">GE Life Sciences/Dharmacon</td><td valign="top">L-005125-00-0020</td><td valign="top"/></tr><tr><td valign="top">Sequenced-based reagent</td><td valign="top">qPCR primers</td><td valign="top">IDT</td><td valign="top"/><td valign="top">See table in Materials and methods</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">ATF4 (cDNA amplified from plasmid)</td><td valign="top">Addgene</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_21845">Addgene_21845</ext-link></td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Pspax2 (plasmid)</td><td valign="top">Addgene</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12260">Addgene_12260</ext-link></td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">Pmd2.G (plasmid)</td><td valign="top">Addgene</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_12259">Addgene_12259</ext-link></td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pSpCas9n(BB)−2A-GFP (PX461) (plasmid)</td><td valign="top">Addgene</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_48140">Addgene_48140</ext-link></td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pTRIPZ (plasmid)</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/27088857">27088857</ext-link></td><td valign="top"/><td valign="top">Alex Toker (Beth Israel Deaconess Medical Center)</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">GFP (cDNA amplified from plasmid)</td><td valign="top">Addgene</td><td valign="top">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:Addgene_19319">Addgene_19319</ext-link></td><td valign="top"/></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">SLC7A11 (cDNA amplified from plasmid)</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29259101">29259101</ext-link></td><td valign="top"/><td valign="top">Alex Toker (Beth Israel Deaconess Medical Center)</td></tr><tr><td valign="top">Recombinant DNA reagent</td><td valign="top">pBabe hygro IRES-TSC2</td><td valign="top">PMID:<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/15150095">15150095</ext-link></td><td valign="top"/><td valign="top">David Kwiatkowski (Brigham and Women’s Hospital)</td></tr><tr><td valign="top">Sequenced-based reagent</td><td valign="top">CRISPR-Cas9n guides for KO of ATF4</td><td valign="top">IDT</td><td valign="top"/><td valign="top">CACCGGAGGTGGAGGGGCTATGCT; AAACAGCATAGCCCCTCCACCTCC; CACCGACAATCTGCCTTCTCCAGG; AAACCCTGGAGAAGGCAGATTGTC</td></tr><tr><td valign="top">Sequenced-based reagent</td><td valign="top">Sequencing primers for Atf4<sup>-/-</sup> cell lines</td><td valign="top">IDT</td><td valign="top"/><td valign="top">TCGATGCTCTGTTTCGAATG; CTTCTTCCCCCTTGCCTTAC</td></tr><tr><td valign="top">Sequenced-based reagent</td><td valign="top">Primers for site-directed mutagenesis</td><td valign="top">IDT</td><td valign="top"/><td valign="top">GCCTCCTGCTCAGCCGCCGCCGCCTCGAGGTACCCAGTGGCTGCTGTCTTGTTTTGCTCCATCT; AGATGGAGCAAAACAAGACAGCAGCCACTGGGTACCTCGAGGCGGCGGCGGCTGAGCAGGAGGC</td></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">KOD Xtreme Hot Start DNA Polymerase</td><td valign="top">Sigma-Aldrich</td><td valign="top">71975</td><td valign="top"/></tr><tr><td valign="top">Antibody</td><td valign="top">(P)-S6K1 T389 <break/>rabbit monoclonal</td><td valign="top">Cell Signaling Technologies (CST)</td><td valign="top">Cat #: 9234 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2269803">AB_2269803</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">ATF4 <break/>rabbit monoclonal</td><td valign="top">Cell Signaling Technologies (CST)</td><td valign="top">Cat #: 11815 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2616025">AB_2616025</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">eIF2α rabbit polyclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 9722 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2230924">AB_2230924</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">P-eIF2α S51 <break/>rabbit polyclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 9721 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330951">AB_330951</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">S6K1 <break/>rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 2708 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_390722">AB_390722</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">CD98 <break/>rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 13180 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687475">AB_2687475</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">PSAT1 rabbit polyclonal</td><td valign="top">Protein Tech</td><td valign="top">Cat #: 20180-1-AP <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10665948">AB_10665948</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">MTHFD2 <break/>rabbit polyclonal</td><td valign="top">Protein Tech</td><td valign="top">Cat #: 12270–1-AP <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2147525">AB_2147525</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">AARS rabbit polyclonal</td><td valign="top">Bethyl Antibodies</td><td valign="top">A303-475A-M</td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">GARS rabbit polyclonal</td><td valign="top">Bethyl Antibodies</td><td valign="top">A304-746A-M</td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">LARS rabbit polyclonal</td><td valign="top">Bethyl Antibodies</td><td valign="top">A304-316A-M</td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">XPOT rabbit polyclonal</td><td valign="top">Aviva Biotechnologies</td><td valign="top">Cat #: ARP40711_P050 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2048757">AB_2048757</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">TSC2 <break/>rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 4308 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10547134">AB_10547134</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">SLC7A11 rabbit monoclonal</td><td valign="top">Abcam</td><td valign="top">Cat #: ab175186 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2722749">AB_2722749</ext-link></td><td valign="top">1:1000, 10 μL <break/>For immunoblots of WT and <italic>Tsc2<sup>-/-</sup></italic> MEFs</td></tr><tr><td valign="top">Antibody</td><td valign="top">SLC7A11 rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 12691 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687474">AB_2687474</ext-link></td><td valign="top">1:1000, 10 μL <break/>For immunoblots of PC3 and LNCaP cell lines</td></tr><tr><td valign="top">Antibody</td><td valign="top">GCLC rabbit monoclonal</td><td valign="top">Abcam</td><td valign="top">ab190685</td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">GCLM rabbit monoclonal</td><td valign="top">Abcam</td><td valign="top">Cat#: ab126704 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_11127439">AB_11127439</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">RICTOR rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 9476 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10612959">AB_10612959</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">RHEB rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 13879 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2721022">AB_2721022</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">4EBP1 rabbit monoclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 9644 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2097841">AB_2097841</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">c-MYC rabbit polyclonal</td><td valign="top">Cell Signaling Technologies</td><td valign="top">Cat #: 9402 RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2151827">AB_2151827</ext-link></td><td valign="top">1:1000, 10 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">β-Actin mouse monoclonal</td><td valign="top">Sigma</td><td valign="top">Cat #: A5316 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_476743">AB_476743</ext-link></td><td valign="top">1:5000, 2 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">HRP-conjugated anti-rabbit rabbit polyclonal</td><td valign="top">CST</td><td valign="top">Cat #: 7074 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2099233">AB_2099233</ext-link></td><td valign="top">1:5000, 2 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">HRP-conjugated anti-mouse mouse polyclonal</td><td valign="top">CST</td><td valign="top">Cat #: 7076 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330924">AB_330924</ext-link></td><td valign="top">1:5000, 2 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">IRDye 800CW Donkey anti-Rabbit IgG rabbit polyclonal</td><td valign="top">LI-COR</td><td valign="top">Cat #: 925–32213 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2715510">AB_2715510</ext-link></td><td valign="top">1:5000, 2 μL</td></tr><tr><td valign="top">Antibody</td><td valign="top">IRDye 800CW Donkey anti-Mouse IgG mouse polyclonal</td><td valign="top">LI-COR</td><td valign="top">Cat #: 926-32212 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_621847">AB_621847</ext-link></td><td valign="top">1:5000, 2 μL</td></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Doxycycline hydrochloride</td><td valign="top">Sigma</td><td valign="top">D3447</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Rapamycin</td><td valign="top">LC Laboratories</td><td valign="top">R5000</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Insulin</td><td valign="top">Alpha Diagnostic,</td><td valign="top">INSL 16 N-5</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Tunicamycin</td><td valign="top">Sigma-Aldrich</td><td valign="top">T7765</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Torin1</td><td valign="top">Tocris</td><td valign="top">4247</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Erastin</td><td valign="top">Selleckchem</td><td valign="top">S7242</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Buthionine-sulfoximine (BSO)</td><td valign="top">Sigma</td><td valign="top">B2515</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Hygromycin B</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">10687010</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Puromycin</td><td valign="top">Sigma</td><td valign="top">P8833</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Staurosporine</td><td valign="top">Tocris</td><td valign="top">1285</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cysteine</td><td valign="top">Sigma</td><td valign="top">C7477</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">Cystine</td><td valign="top">Sigma</td><td valign="top">57579</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">2-Mercaptoethanol</td><td valign="top">EMD Millipore</td><td valign="top">444203</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">MEM Nonessential amino acids solution</td><td valign="top">Thermo Fisher <break/>Scientific</td><td valign="top">11140050</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top"><sup>35</sup>S-methionine</td><td valign="top">PerkinElmer</td><td valign="top">NEG009L005MC</td><td valign="top"/></tr><tr><td valign="top">Chemical compound, drug</td><td valign="top">L-[1, 2, 1', 2'-<sup>14</sup>C]-Cystine</td><td valign="top">PerkinElmer</td><td valign="top">NEC854010UC</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">FITC Annexin V Apoptosis Detection Kit I</td><td valign="top">BD</td><td valign="top">556547</td><td valign="top"/></tr><tr><td valign="top">Commercial assay or kit</td><td valign="top">GSH/GSSG-Glo Assay</td><td valign="top">Promega</td><td valign="top">V6611</td><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture</title><p>MEFs and PC3 cells were maintained in DMEM (Corning/Cellgro, 10-017-CV) with 10% fetal bovine serum (FBS, Corning/Gibco). LNCaP cells were maintained in RPMI-1640 (Corning/Cellgro 10-040-CV) with 10% FBS. <italic>Tsc2<sup>-/-</sup></italic> (<italic>p53<sup>-/-</sup></italic>) MEFs and littermate-derived wild-type counterparts were provided by David Kwiatkowski (Brigham and Women’s Hospital, Boston, MA). <italic>eIF2α<sup>S/S</sup></italic> (WT) and <italic>eIF2α<sup>A/A</sup></italic> (S51A knock-in mutant) MEFs were provided by Randal Kaufman (Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA) and were not used above passage 3 (after received). <italic>Rictor<sup>+/+</sup></italic> and <italic>Rictor<sup>-/-</sup></italic> MEFs were provided by D.A. Guertin and D.M. Sabatini (Whitehead Institute, Massachusetts Institute of Technology, Cambridge, MA). Cancer cell lines were obtained from ATCC. <italic>Atf4<sup>-/-</sup></italic> MEF lines generated in this study were maintained in DMEM with 10% FBS, supplemented with 55 µM 2-mercaptoethanol (Thermo, 21985023), and 1X MEM NEAA mix (NEAA, final concentrations: 100 µM each of alanine, aspartate, asparagine, glutamate, glycine, proline, and serine; Thermo 11140050). In experiments with supplementation of excess cysteine, cells were plated in DMEM with 10% FBS, 1 mM cysteine, and, where indicated, 1X MEM NEAA mix.</p></sec><sec id="s4-2"><title>siRNA knockdowns</title><p>Cells were transfected with 20 nM of the indicated siRNAs using Opti-MEM (Thermo, 31985062) and RNAimax (Thermo, 13778150) according to the manufacturer’s protocol. siRNAs were from GE Life Sciences/Dharmacon: non-targeting pool (D-001810-10-50), <italic>Myc</italic> (L-040813-00-0010), <italic>Atf4</italic> (mouse, L-042737-01-0020), <italic>Rheb</italic> (L-057044-00-0020), <italic>RhebL1</italic> (L-056074-01-0020), <italic>Tsc2</italic> (L-047050-00-0020), C/ebpα (L-040561-00-0005), C/ebpβ (L-043110-00-0005), C/ebpδ (L-060294-01-0005), C/ebpγ (L-065627-00-0005), and <italic>ATF4</italic> (human, L-005125-00-0020). Forty-eight hours post transfection, cells were treated as indicated prior to lysis for immunoblotting, RNA extraction, or protein synthesis assays. For C/EBP isoform knockdown experiments, transfection of siRNAs was performed a second time, 24 hr after the first transfection. For protein synthesis assays involving siRNAs, transfection was also performed a second time, 24 hr after the first transfection, which was necessary to achieve sufficient knockdown of Rheb to reduce mTORC1 signaling.</p></sec><sec id="s4-3"><title>Generation and validation of <italic>Atf4<sup>-/-</sup></italic> and reconstituted cell lines</title><p><italic>Tsc2<sup>+/+</sup></italic> (WT) and <italic>Tsc2<sup>-/-</sup></italic> MEFs lacking Atf4 were generated by CRISPR-Cas9-mediated deletion using pSpCas9n(BB)−2A-GFP (PX461) vector (Addgene, 48140) according to the previously described protocol (<xref ref-type="bibr" rid="bib50">Ran et al., 2013</xref>). The paired nickase guides were designed using E-CRISP (<xref ref-type="bibr" rid="bib23">Heigwer et al., 2014</xref>) and targeted the sequences <named-content content-type="sequence">AGCATAGCCCCTCCACCTCC</named-content> and <named-content content-type="sequence">GACAATCTGCCTTCTCCAGG</named-content> in exon 2 of ATF4. Forty-eight hours post transfection, single GFP-positive cells were sorted into 96-well plates. Cells were cultured in DMEM with 10% FBS supplemented with 1X MEM NEAA and 55 µM 2-mercaptoethanol. Single cell clones were grown for immunoblot analysis, and those showing loss of ATF4 protein were selected for sequence analysis involving the isolation of genomic DNA (Qiagen, 69504), PCR amplification using KOD Xtreme Hot Start DNA Polymerase (Millipore, 71975), and the primers <named-content content-type="sequence">TCGATGCTCTGTTTCGAATG</named-content> and <named-content content-type="sequence">CTTCTTCCCCCTTGCCTTAC</named-content> flanking the targeted deletion site, with sequencing on an ABI3730xl DNA analyzer at the DNA Resource Core of Dana-Farber/Harvard Cancer Center (funded in part by NCI Cancer Center support grant 2P30CA006516-48). The mutations were identified using CRISP-ID software (<xref ref-type="bibr" rid="bib12">Dehairs et al., 2016</xref>). For the final clones selected, the mutations generated in the WT MEFs include an out-of-frame 17-bp deletion starting at the codon encoding T237 and a large out-of-frame 73-bp deletion starting after the codon encoding G219, both resulting in premature STOP codons. The mutations generated in the <italic>Tsc2<sup>-/-</sup></italic> MEFs include an out-of-frame 245-bp deletion starting at the codon encoding G190, resulting in a premature STOP codon after the D191 codon, and an in-frame deletion removing the sequences encoded between E210 and E284.</p><p>For generation of <italic>Atf4</italic> expression vectors, the murine <italic>Atf4</italic> cDNA was amplified from the plasmid 21845 from Addgene (<xref ref-type="bibr" rid="bib20">Harding et al., 2000</xref>). Restriction enzyme cloning with AgeI and ClaI was used to insert the <italic>Atf4</italic>-coding sequence (lacking the 5′ and 3′-UTR) into the pTRIPZ plasmid for doxycycline-inducible expression. The ATF4<sup>DBD</sup> mutant, in which amino acids 292–298 of the DNA-binding domain are changed from RYRQKKR to GYLEAAA (<xref ref-type="bibr" rid="bib22">He et al., 2001</xref>; <xref ref-type="bibr" rid="bib34">Lange et al., 2008</xref>), was generated by DpnI-mediated site-directed mutagenesis using KOD Xtreme Hot Start DNA Polymerase. The dox-inducible pTRIPZ and SLC7A11 plasmids were a gift from Alex Toker (Beth Israel Deaconess Medical Center, Boston, MA). cDNA expression was induced with 1 μg/mL of doxycycline (Sigma-Aldrich, D3447) for 12–24 hr before assays were conducted. GFP was inserted into pTRIPZ to produce the control vector. Lentivirus was generated in HEK293T cells transfected with pMD2.G and psPAX2 (Addgene, 12259 and 12260) and the given pTRIPZ constructs. Forty-eight hours post transfection, the virus-containing medium was used to infect the <italic>Atf4</italic> knockout cells, which were selected with 8 μg/mL puromycin. TSC2 addback cell lines were generated by retroviral infection following transfection of PT67 cells with pBabe hygro IRES-EV or pBabe hygro IRES-TSC2. Cells were selected with 400 μg/mL hygromycin B (Thermo, 10687010).</p></sec><sec id="s4-4"><title>RNA-sequencing</title><p>Wild-type and <italic>Atf4<sup>-/-</sup></italic> MEFs were grown to 70% confluence in 6 cm plates and were serum-starved in the presence of 2-mercaptoethanol and 1X MEM NEAA mixture and treated with vehicle (DMSO) or 20 nM rapamycin (LC Laboratories, R5000) for 30 min prior to stimulation with vehicle (water) or 500 nM insulin (Alpha Diagnostic, INSL 16 N-5) for 16 hr or treated with vehicle (DMSO) or 2 μg/mL tunicamycin (Sigma-Aldrich, T7765) for 4, 8, or 16 hr. RNA was harvested with TRIzol according to the manufacturer’s protocol (Thermo, 15596018). All samples passed RNA quality control measured by NanoDrop 1000 Spectrophotometer (NanoDrop Technologies) and 2100 Bioanalyzer (Agilent Technologies). cDNA libraries were generated to produce 150-bp paired-end reads on an Illumina NovaSeq with read depth of 20 million paired reads per sample. Reads were aligned and annotated to the Ensembl <italic>Mus musculus</italic> GRCm38.p6 genome assembly using the align and featureCounts functions from the Rsubread package (2.0.1) in R (3.6.3) (<xref ref-type="bibr" rid="bib38">Liao et al., 2019</xref>). Differential gene expression analysis was performed using the voom and eBayes functions from the EgdeR (3.28.1) and Limma (3.42.2) packages, respectively (<xref ref-type="bibr" rid="bib53">Ritchie et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Robinson et al., 2010</xref>). Transcripts found to be significantly induced by tunicamycin were further limited to those with a greater than 1.2-fold increase. The enrichKEGG function from the clusterProfiler package (3.14.3) was used to perform KEGG pathway over-representation tests (<xref ref-type="bibr" rid="bib77">Yu et al., 2012</xref>). Gene set enrichment analysis was evaluated using GSEA software from the Broad Institute (<xref ref-type="bibr" rid="bib60">Subramanian et al., 2005</xref>). Computations were run on the FASRC Cannon cluster, supported by the Faculty of Arts and Sciences Division of Science Research Computing Group at Harvard University. Pseudogenes and unannotated genes were excluded from <xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. The complete RNA-seq data can be found at GEO under the accession number GSE158605.</p></sec><sec id="s4-5"><title>CiiiDER analysis</title><p>CiiiDER software was downloaded from <ext-link ext-link-type="uri" xlink:href="http://ciiider.org/">CiiiDER.org</ext-link> with the <italic>M. musculus</italic> GRCm38.94 genome files. Searches were run against the JASPAR transcription factor-binding profile database. Searches were run on promoter regions spanning +1500 to −500 bp from the predicted transcriptional start site using a site identification deficit threshold of 0.1. The background gene list (ISR only) comprised the 200 ATF4-dependent genes most significantly increased in expression upon tunicamycin treatment that were not in the list of 61 genes shared in their regulation by mTORC1 signaling and the ISR. Results of this analysis are included in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>.</p></sec><sec id="s4-6"><title>Cistrome analysis</title><p>Each of the 61 shared mTORC1 and ISR genes was analyzed using the CistromeDB Toolkit (<ext-link ext-link-type="uri" xlink:href="http://dbtoolkit.cistrome.org/">http://dbtoolkit.cistrome.org/</ext-link>) of existing genome-wide ChIP-seq data. A half-decay distance of 1 kb to the transcription start site was used. The top 20 transcription factors or chromatin regulators found in ChIP-seq experiments to bind to each gene were compiled, and the number of genes each factor bound to within the list of 61 was determined, with the top 9 regulators graphed, excluding the general factors EP300 and POL2RA.</p></sec><sec id="s4-7"><title>Immunoblotting</title><p>Cells were lysed in ice-cold Triton lysis buffer (40 mM HEPES pH 7.4, 120 mM NaCl, 1 mM EDTA, 1% Triton X-100, 10 mM sodium pyrophosphate, 10 mM glycerol 2-phosphate, 50 mM NaF, 0.5 mM sodium orthovanadate, 1 μM Microcystin-LR, and Sigma protease inhibitor cocktail P8340). For immunoblots on SLC7A11, cells were lysed in 1% SDS lysis buffer (10 mM Tris pH 7.4, 1 mM EDTA, 10 mM sodium pyrophosphate, 10 mM glycerol 2-phosphate, 50 mM NaF, 0.5 mM sodium orthovanadate, and Sigma protease inhibitor cocktail P8340). Samples were centrifuged at 20,000 × <italic>g</italic> for 10 min at 4°C, and protein concentration in the supernatant was determined by Bradford assay (Bio-Rad, 5000202) and normalized across samples. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and immunoblotted with indicated antibody. Primary antibodies used were MTHFD2 (Protein Tech, 12270-1-AP), PSAT1 (Protein Tech 20180-1-AP), phospho (P)-S6K1 T389 (Cell Signaling Technologies [CST], 9234), ATF4 (CST, 11815), eIF2α (CST, 9722), P-eIF2α S51 (CST, 9721), S6K1 (CST, 2708), CD98 (CST, 13180), AARS (Bethyl Antibodies, A303-475A-M), GARS (Bethyl Antibodies, A304-746A-M), LARS (Bethyl Antibodies, A304-316A-M), XPOT (Aviva Biotechnologies, ARP40711_P050), TSC2 (CST, 4308), SLC7A11 (mouse, Abcam, ab175186), SLC7A11 (human, CST, 12691), GCLC (Abcam, ab190685), GCLM (Abcam, ab126704), RICTOR (CST, 9476), RHEB (CST, 13879), 4EBP1 (CST 9644), c-MYC (CST, 9402), and β-actin (Sigma-Aldrich, A5316); secondary antibodies used were IRDye 800CW Donkey anti-Mouse IgG (H + L) (LI-COR, 926-32212) and Donkey anti-Rabbit IgG (H + L) (LI-COR, 925–32213), and HRP-conjugated anti-mouse and anti-rabbit secondary antibodies from (CST, 7074 and 7076). Immunoblots of MTHFD2, PSAT1, AARS, GARS, LARS, and XPOT were imaged using Odyssey CLx Imaging System (LI-COR Biosciences). β-Actin was developed with Odyssey CLx Imaging System or enhanced chemiluminescence assay (ECL). All remaining immunoblots were developed using ECL. Immunoblots were quantified using the Odyssey CLx Imaging System and were normalized to β-actin. The ATF4 immunoblot corresponding to <xref ref-type="fig" rid="fig1">Figure 1B</xref> (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) and the SLC7A11 immunoblots in <xref ref-type="fig" rid="fig6">Figure 6D, E</xref> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B, C</xref>) was quantified using ImageJ and normalized to β-actin.</p></sec><sec id="s4-8"><title>NanoString analysis</title><p>RNA was harvested using TRIzol from cells at 70% confluence. All samples passed RNA quality control measured by NanoDrop 1000 Spectrophotometer. Parallel plates were lysed for immunoblots. The isolated RNA was analyzed using a custom NanoString probe library according to the manufacturer’s instructions (NanoString Technologies). Briefly, sample RNA was hybridized to RNA-probes at 65°C for 16 hr, excess probe was washed away, and an nCounter SPRINT was used to quantify specific mRNA molecules present in each sample. Direct mRNA counts were normalized to internal control genes, and mRNA expression was analyzed using nSOLVER software. Heatmaps were generated with Morpheus software from the Broad Institute (<ext-link ext-link-type="uri" xlink:href="https://software.broadinstitute.org/morpheus">https://software.broadinstitute.org/morpheus</ext-link>). Transcripts with 100 counts or fewer, a value based off of negative control samples, were not included in our analyses. Results of this analysis are included in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p></sec><sec id="s4-9"><title>qPCR</title><p>For gene expression analysis, RNA was isolated with TRIzol according to the manufacturer’s protocol. All samples passed RNA quality control measured by NanoDrop 1000 Spectrophotometer. cDNA was generated with Superscript III First Strand Synthesis System for RT-PCR (Thermo, 18080051). Quantitative RT-PCR was performed with a CFX Connect Realtime PCR Detection System (Bio-Rad) using iTaq Universal SYBR Green Supermix (Bio-Rad, 1725125). Samples were quantified by the ∆∆CT method, normalized to <italic>β-actin</italic> (mouse samples) or <italic>RPLP0</italic> (human samples) to quantify relative mRNA expression levels. qPCR primers:</p><p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td valign="top"><italic>Atf4</italic></td><td valign="top"><named-content content-type="sequence">GATGGGTTCTCCAGCGACAAG</named-content></td><td valign="top"><named-content content-type="sequence">CCGGAAAAGGCATCCTCCTTC</named-content></td></tr><tr><td valign="top"><italic>Psat1</italic></td><td valign="top"><named-content content-type="sequence">GCTGTCGCCTTAGCACCA</named-content></td><td valign="top"><named-content content-type="sequence">TGGATCTCCAACAATACCGAGTG</named-content></td></tr><tr><td valign="top"><italic>Mthfd2</italic></td><td valign="top"><named-content content-type="sequence">TCCTTGTTGTCTGCGTTGGC</named-content></td><td valign="top"><named-content content-type="sequence">CTTCATTTCGCACTGCCGCC</named-content></td></tr><tr><td valign="top"><italic>Slc7a5</italic></td><td valign="top"><named-content content-type="sequence">GGACAAGGTGATGCGTCCAA</named-content></td><td valign="top"><named-content content-type="sequence">GCCAACACAATGTTCCCCAC</named-content></td></tr><tr><td valign="top"><italic>Aars</italic></td><td valign="top"><named-content content-type="sequence">TTGCTATTCCCTCGGAGCAC</named-content></td><td valign="top"><named-content content-type="sequence">CTCCTCGGGAACCTTAGCTC</named-content></td></tr><tr><td valign="top"><italic>Gars</italic></td><td valign="top"><named-content content-type="sequence">GGCAGAGGTCTCTGAGCTG</named-content></td><td valign="top"><named-content content-type="sequence">GCACGATGGTCATAAGCTGC</named-content></td></tr><tr><td valign="top"><italic>Cars</italic></td><td valign="top"><named-content content-type="sequence">GAGCAGGCTGCCGACTACA</named-content></td><td valign="top"><named-content content-type="sequence">TATAGCTACGCGTGCTGAGG</named-content></td></tr><tr><td valign="top"><italic>Nars</italic></td><td valign="top"><named-content content-type="sequence">GAGCCGGCCTGTGTAAAGAT</named-content></td><td valign="top"><named-content content-type="sequence">GACCCAGCCAAACACCTTCA</named-content></td></tr><tr><td valign="top"><italic>Iars</italic></td><td valign="top"><named-content content-type="sequence">TATTGCATCACCTCCAGACGC</named-content></td><td valign="top"><named-content content-type="sequence">TGAACCATTCTGTTGCTGGGA</named-content></td></tr><tr><td valign="top"><italic>Gclc</italic></td><td valign="top"><named-content content-type="sequence">TGTACTCCACCCTCGTCACCC</named-content></td><td valign="top"><named-content content-type="sequence">CTGCTGTCCCAAGGCTCG</named-content></td></tr><tr><td valign="top"><italic>Gclm</italic></td><td valign="top"><named-content content-type="sequence">TGGGCACAGGTAAAACCCAA</named-content></td><td valign="top"><named-content content-type="sequence">CTGGGCTTCAATGTCAGGGA</named-content></td></tr><tr><td valign="top"><italic>Slc7a11</italic></td><td valign="top"><named-content content-type="sequence">ATCTCCCCCAAGGGCATACT</named-content></td><td valign="top"><named-content content-type="sequence">GCATAGGACAGGGCTCCAAA</named-content></td></tr><tr><td valign="top"><italic>Slc3a2</italic></td><td valign="top"><named-content content-type="sequence">TGATGAATGCACCCTTGTACTTG</named-content></td><td valign="top"><named-content content-type="sequence">GCTCCCCAGTGAAAGTGGA</named-content></td></tr><tr><td valign="top"><italic>Slc1a5</italic></td><td valign="top"><named-content content-type="sequence">GTAAAATACCGCAATCCTGTATCC</named-content></td><td valign="top"><named-content content-type="sequence">CGATAGCGAAGACCACCAGG</named-content></td></tr><tr><td valign="top"> <italic>Xpot</italic></td><td valign="top"><named-content content-type="sequence">GCTTCAGGCTCAGATGCAGA</named-content></td><td valign="top"><named-content content-type="sequence">AAAGCAAGGCGAACACTTGG</named-content></td></tr><tr><td valign="top"><italic>c-Myc</italic></td><td valign="top"><named-content content-type="sequence">AGAGCTCCTCGAGCTGTTTG</named-content></td><td valign="top"><named-content content-type="sequence">TTCTCTTCCTCGTCGCAGAT</named-content></td></tr><tr><td valign="top"><italic>C/ebpα</italic></td><td valign="top"><named-content content-type="sequence">CAAGAACAGCAACGAGTACCG</named-content></td><td valign="top"><named-content content-type="sequence">GTCACTGGTCAACTCCAGCAC</named-content></td></tr><tr><td valign="top"><italic>C/ebpβ</italic></td><td valign="top"><named-content content-type="sequence">CGCCTTATAAACCTCCCGCT</named-content></td><td valign="top"><named-content content-type="sequence">TGGCCACTTCCATGGGTCTA</named-content></td></tr><tr><td valign="top"><italic>C/ebpδ</italic></td><td valign="top"><named-content content-type="sequence">CGACTTCAGCGCCTACATTGA</named-content></td><td valign="top"><named-content content-type="sequence">CTAGCGACAGACCCCACAC</named-content></td></tr><tr><td valign="top"><italic>C/ebpγ</italic></td><td valign="top"><named-content content-type="sequence">TCGGATCACATTGCTCTGATTTC</named-content></td><td valign="top"><named-content content-type="sequence">TGTGCCTGAGTATGAATGACACT</named-content></td></tr><tr><td valign="top"><italic>Actin</italic></td><td valign="top"><named-content content-type="sequence">CACTGTCGAGTCGCGTCC</named-content></td><td valign="top"><named-content content-type="sequence">TCATCCATGGCGAACTGGTG</named-content></td></tr><tr><td valign="top"><italic>PSAT1</italic></td><td valign="top"><named-content content-type="sequence">AAAAACAATGGAGGTGCCGC</named-content></td><td valign="top"><named-content content-type="sequence">GGCTCCACTGGACAAACGTA</named-content></td></tr><tr><td valign="top"><italic>ASNS</italic></td><td valign="top"><named-content content-type="sequence">TGGCTGCCTTTTATCAGGGG</named-content></td><td valign="top"><named-content content-type="sequence">TCTGCCACCTTTCTAGCAGC</named-content></td></tr><tr><td valign="top"><italic>MTHFD2</italic></td><td valign="top"><named-content content-type="sequence">GGCAGTTCGAAATGAAGCTGTT</named-content></td><td valign="top"><named-content content-type="sequence">GCCAACCAGGATCACACTCA</named-content></td></tr><tr><td valign="top"><italic>SLC7A5</italic></td><td valign="top"><named-content content-type="sequence">GACTACGCCTACATGCTGGA</named-content></td><td valign="top"><named-content content-type="sequence">AGCAGCAGCACGCAGAG</named-content></td></tr><tr><td valign="top"><italic>AARS</italic></td><td valign="top"><named-content content-type="sequence">CCATTCAGAAGGGCACAGGT</named-content></td><td valign="top"><named-content content-type="sequence">TATCCACGCCCTGTGTTGTC</named-content></td></tr><tr><td valign="top"><italic>GARS</italic></td><td valign="top"><named-content content-type="sequence">GCCAGCAGGGAGATCTTGTG</named-content></td><td valign="top"><named-content content-type="sequence">CCAGCTCCTTTGCTTCCAGA</named-content></td></tr><tr><td valign="top"><italic>XPOT</italic></td><td valign="top"><named-content content-type="sequence">GACGCAGAGCGACTAGAGG</named-content></td><td valign="top"><named-content content-type="sequence">TAAACATCTTCCCTATCACTCCATC</named-content></td></tr><tr><td valign="top"><italic>SLC7A11</italic></td><td valign="top"><named-content content-type="sequence">AAGGTGCCACTGTTCATCCC</named-content></td><td valign="top"><named-content content-type="sequence">ATGTTCTGGTTATTTTCTCCGACA</named-content></td></tr><tr><td valign="top"><italic>RPLP0</italic></td><td valign="top"><named-content content-type="sequence">CCTCGTGGAAGTGACATCGT</named-content></td><td valign="top"><named-content content-type="sequence">ATCTGCTTGGAGCCCACATT</named-content></td></tr></tbody></table></table-wrap></p></sec><sec id="s4-10"><title>Protein synthesis assay</title><p>Cells were cultured as indicated, washed twice with PBS, and changed to methionine/cystine/glutamine-free DMEM (Thermo, 21013024) supplemented with 0.5 mM L-cystine (Sigma, 57579) and L-glutamine (4 mM) with 50 μCi/mL <sup>35</sup>S-methionine (PerkinElmer, NEG009L005MC) for 20 min. Cells were washed twice in ice-cold PBS and lysed in ice-cold Triton lysis buffer. Total protein concentrations were normalized following a Bradford assay, and normalized samples were separated by SDS-PAGE and transferred to nitrocellulose. <sup>35</sup>S-methionine incorporation into protein was analyzed by autoradiography, and relative rates of protein synthesis were quantified using ImageJ Software (NIH) to quantify radiolabeled protein per lane for each sample. For isogenic <italic>Atf4<sup>-/-</sup></italic> cell lines, exogenous cDNA expression was induced for 16 hr with 150 ng/mL doxycycline, and cells were treated as indicated in the presence of doxycycline (150 ng/mL) and 1X MEM NEAA mixture plus 1 mM cysteine (Sigma, C7477). Protein synthesis was assayed with 20 min labeling in the absence of NEAA and cysteine to avoid competition of <sup>35</sup>S-methionine uptake with the supplemented amino acids.</p></sec><sec id="s4-11"><title>Methionine and cystine uptake</title><p>For methionine uptake assays, cells were cultured and labeled as described above for the protein synthesis assay, were washed three times in cold PBS, and lysed in Triton lysis buffer. For cystine uptake assays, cells were treated the same but labeled for the final 10 min with medium containing 0.1 µCi L-[1, 2, 1', 2'-<sup>14</sup>C]-Cystine (PerkinElmer, NEC854010UC) and washed three times in ice-cold PBS containing cold cystine (1 mM), prior to lysis in Triton lysis buffer. Whole-cell radiolabel incorporation was quantified with a Beckman LS6500 scintillation counter. Cells from identically treated parallel plates were counted using a Beckman Z1-Coulter Counter to normalize uptake measurements to cell number.</p></sec><sec id="s4-12"><title>Proliferation assay</title><p>To quantify cell proliferation, cells were plated in DMEM in 6-well plates in triplicate in the presence of 2-mercaptoethanol, 1X MEM NEAA mixture, 10% FBS, and doxycycline (1 μg/mL). Twenty-four hours after plating, cells were washed twice with PBS and media was changed to DMEM with 10% dialyzed FBS, doxycycline (1 μg/mL), and the amino acid supplements indicated for each experiment, with media refreshed daily. Starting on day 0, viable cells from triplicate wells corresponding to each condition or cell line were counted using a hemocytometer, excluding dead cells detected by trypan blue stain (Sigma-Aldrich, T8154).</p></sec><sec id="s4-13"><title>Analysis of cell death</title><p>Cells were plated in DMEM in 6-well plates in triplicate in the presence of 2-mercaptoethanol, 1X MEM NEAA mixture, 10% FBS, and doxycycline (1 μg/mL). Twenty-four hours after plating, cells were washed twice with PBS and media was changed to DMEM with 10% dialyzed FBS and doxycycline (1 μg/mL). Seventy-two hours later, cells were detached with Accumax (Sigma-Aldrich, A7089) and washed twice with cold PBS on ice. Cells were stained with annexin V and propidium iodide (PI) according to the manufacturer’s instruction (BD, 556547). Samples were analyzed using an LSRFortessa (BD) flow cytometer, and the fractions of stained cells were quantified using FloJo 10.6, with Staurosporine (4 hr, 5 μM) (Tocris, 1285) used as a positive control for cell death and to help establish gating of the sorted cells.</p></sec><sec id="s4-14"><title>Measurements of cellular and tumor glutathione</title><p>Cells were plated in 96-well plates at 5000 cells/well. Total glutathione, GSH, and GSSG levels were measured using the GSH/GSSG-Glo Assay (Promega, V6611) according to the manufacturer’s protocol. Total glutathione levels were normalized to cell number determined from parallel plates. BSO (Sigma, B2515) was used as a positive control to inhibit glutathione synthesis.</p><p>For measurements via LC-MS/MS, metabolites were extracted from cells on dry ice using 80% methanol, and extracts were dried under nitrogen gas for metabolite profiling via selected reaction monitoring with polarity switching using a 5500 QTRAP mass spectrometer. Data were analyzed using MultiQuant 2.1.1 software (AB/SCIEX) to calculate the Q3 peak area. Normalized peak area of glutathione from human <italic>TSC2<sup>-/-</sup></italic> angiomyolipoma (621-101) cells was determined from previously published data (<xref ref-type="bibr" rid="bib61">Tang et al., 2019</xref>). For xenograft tumor studies, experimental details were provided previously (<xref ref-type="bibr" rid="bib65">Valvezan et al., 2017</xref>). Briefly, mice bearing <italic>TSC2<sup>-/-</sup></italic> ELT3 xenograft tumors were treated every other day for 5 days with vehicle or rapamycin (1 mg/kg on days 1, 3, and 5) and tumors were harvested for metabolite extraction, as above, 3 hr after the final treatment.</p></sec><sec id="s4-15"><title>Statistics</title><p>For RNA-sequencing analysis, Benjamini–Hochberg false discovery rate (FDR)-adjusted p values were determined from empirical Bayes moderated t-statistics using the voom and eBayes functions from the limma package. Comparisons with FDR-adjusted p&lt;0.05 were considered significant for the gene groups denoted compared to vehicle-treated controls. For KEGG enrichment, p values were FDR corrected. For CiiiDER transcription factor over-representation analysis, Fisher's exact test p values were used. Transcription factor binding elements with p&lt;0.01 and test statistic &gt;0 were considered over-represented in genes of interest. Unpaired two-tailed <italic>t</italic>-tests were used for NanoString analyses to calculate p values for rank ordering. All remaining statistical analyses were performed with Prism 8 software (GraphPad Software, La Jolla, CA). Statistical analyses for qPCR data with two treatment groups were determined by unpaired two-tailed <italic>t</italic>-test, while those with greater than two treatment groups were determined by one-way analysis of variance (ANOVA) with Holm–Sidak method for multiple comparisons. Statistical analyses for protein synthesis assays were determined by one-way ANOVA with Holm–Sidak method for multiple comparisons from values quantified with ImageJ software (US National Institutes of Health, Bethesda, MD). Statistical analyses for immunoblot quantification data with two treatment groups were determined by unpaired two-tailed <italic>t</italic>-test, while those with greater than two treatment groups were determined by one-way ANOVA with Holm–Sidak method for multiple comparisons. For proliferation assays, unpaired two-tailed <italic>t</italic>-test was used for comparisons to GFP-expressing cells. For cell death analysis, one-way ANOVA with Holm–Sidak method for multiple comparisons, summing the annexin V+/PI-, annexin V-/PI+, and annexin V+/PI+ populations for each conditions. For glutathione quantification of experiments with two conditions, an unpaired two-tailed <italic>t</italic>-test was performed. For remaining glutathione assays and all cystine and methionine uptake experiments, one-way ANOVA with Holm–Sidak method for multiple comparisons was used.</p></sec><sec id="s4-16"><title>Source data</title><p>The source data for the RNA-sequencing experiment can be found at GEO under the accession number GSE158605. The source data for <xref ref-type="fig" rid="fig1">Figure 1C</xref> can be found in <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>. The source data for <xref ref-type="fig" rid="fig2">Figure 2A</xref> can be found in <xref ref-type="supplementary-material" rid="fig2sdata1">Figure 2—source data 1</xref>. The source data for NanoString heatmaps shown in <xref ref-type="fig" rid="fig3">Figure 3</xref> can be found in <xref ref-type="supplementary-material" rid="fig3sdata1">Figure 3—source data 1</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank David J Kwiatkowski, Elizabeth P Henske, Randal J Kaufman, Alex Toker, and David M Sabatini for cell lines and materials and Min Yuan, Gerta Hoxhaj, and Issam Ben-Sahra for technical assistance and critical discussions. This research was supported by grants from the NIH: T32-ES016645 (MET), F31-CA228332 (MET), R35-CA197459 (BDM), and P01-CA120964 (BDM and JA); the Department of Defense’s Congressionally Directed Medical Research Program on Tuberous Sclerosis Complex, award no. W81XWH-18-1-0659 (BDM); and a research grant from Zafgen (BDM and JRM). BDM is a shareholder and scientific advisory board member of LAM Therapeutics and Navitor Pharmaceuticals. All other authors declare no competing financial interests.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>Brendan Manning is a scientific advisory board member and stockholder of Navitor Pharmaceuticals and LAM Therapeutics.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Supervision, Funding acquisition, Project administration</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal procedures were conducted under strict adherence to recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and were approved by the Harvard Institutional Animal Care and Use Committee (#IS00000780).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-63326-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1, 2, and 3. RNA-Seq data have been deposited in GEO under accession code GSE158605.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>MacArthur</surname><given-names>MR</given-names></name><name><surname>Manning</surname><given-names>BD</given-names></name><name><surname>Torrence</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis (Tunicamycin)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE158605">GSE158605</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Role of the transcription factor ATF4 in the anabolic actions of insulin and the anti-anabolic actions of glucocorticoids</article-title><source>Journal of Biological Chemistry</source><volume>282</volume><fpage>16744</fpage><lpage>16753</lpage><pub-id pub-id-type="doi">10.1074/jbc.M610510200</pub-id><pub-id pub-id-type="pmid">17430894</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname> <given-names>GJ</given-names></name><name><surname>Kuersten</surname> <given-names>S</given-names></name><name><surname>Romby</surname> <given-names>P</given-names></name><name><surname>Ehresmann</surname> <given-names>B</given-names></name><name><surname>Mattaj</surname> <given-names>IW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The role of exportin-t in selective nuclear export of mature tRNAs</article-title><source>The EMBO Journal</source><volume>17</volume><fpage>7430</fpage><lpage>7441</lpage><pub-id pub-id-type="doi">10.1093/emboj/17.24.7430</pub-id><pub-id pub-id-type="pmid">9857198</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannai</surname> <given-names>S</given-names></name><name><surname>Kitamura</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Transport interaction of L-cystine and L-glutamate in human diploid fibroblasts in culture</article-title><source>Journal of Biological Chemistry</source><volume>255</volume><fpage>2372</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(19)85901-X</pub-id><pub-id pub-id-type="pmid">7358676</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Sahra</surname> <given-names>I</given-names></name><name><surname>Hoxhaj</surname> <given-names>G</given-names></name><name><surname>Ricoult</surname> <given-names>SJH</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle</article-title><source>Science</source><volume>351</volume><fpage>728</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1126/science.aad0489</pub-id><pub-id pub-id-type="pmid">26912861</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugarolas</surname> <given-names>JB</given-names></name><name><surname>Vazquez</surname> <given-names>F</given-names></name><name><surname>Reddy</surname> <given-names>A</given-names></name><name><surname>Sellers</surname> <given-names>WR</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>TSC2 regulates VEGF through mTOR-dependent and -independent pathways</article-title><source>Cancer Cell</source><volume>4</volume><fpage>147</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1016/S1535-6108(03)00187-9</pub-id><pub-id pub-id-type="pmid">12957289</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugarolas</surname> <given-names>J</given-names></name><name><surname>Lei</surname> <given-names>K</given-names></name><name><surname>Hurley</surname> <given-names>RL</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name><name><surname>Reiling</surname> <given-names>JH</given-names></name><name><surname>Hafen</surname> <given-names>E</given-names></name><name><surname>Witters</surname> <given-names>LA</given-names></name><name><surname>Ellisen</surname> <given-names>LW</given-names></name><name><surname>Kaelin</surname> <given-names>WG</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex</article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>2893</fpage><lpage>2904</lpage><pub-id pub-id-type="doi">10.1101/gad.1256804</pub-id><pub-id pub-id-type="pmid">15545625</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clemens</surname> <given-names>MJ</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Protein kinases that phosphorylate eIF2 and eIF2B, and their role in eukaryotic cell translational control</article-title><source>Translational Control</source><volume>30</volume><fpage>139</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1101/0.139-172</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname> <given-names>DM</given-names></name><name><surname>Won</surname> <given-names>KJ</given-names></name><name><surname>Nguyen</surname> <given-names>N</given-names></name><name><surname>Lazar</surname> <given-names>MA</given-names></name><name><surname>Chen</surname> <given-names>CS</given-names></name><name><surname>Steger</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>ATF4 licenses C/EBPβ activity in human mesenchymal stem cells primed for adipogenesis</article-title><source>eLife</source><volume>4</volume><elocation-id>e06821</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.06821</pub-id><pub-id pub-id-type="pmid">26111340</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condon</surname> <given-names>KJ</given-names></name><name><surname>Orozco</surname> <given-names>JM</given-names></name><name><surname>Adelmann</surname> <given-names>CH</given-names></name><name><surname>Spinelli</surname> <given-names>JB</given-names></name><name><surname>van der Helm</surname> <given-names>PW</given-names></name><name><surname>Roberts</surname> <given-names>JM</given-names></name><name><surname>Kunchok</surname> <given-names>T</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genome-wide CRISPR screens reveal multitiered mechanisms through which mTORC1 senses mitochondrial dysfunction</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2022120118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2022120118</pub-id><pub-id pub-id-type="pmid">33483422</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conrad</surname> <given-names>M</given-names></name><name><surname>Sato</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The oxidative stress-inducible cystine/glutamate antiporter, system x (c) (-) : cystine supplier and beyond</article-title><source>Amino Acids</source><volume>42</volume><fpage>231</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1007/s00726-011-0867-5</pub-id><pub-id pub-id-type="pmid">21409388</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csibi</surname> <given-names>A</given-names></name><name><surname>Lee</surname> <given-names>G</given-names></name><name><surname>Yoon</surname> <given-names>SO</given-names></name><name><surname>Tong</surname> <given-names>H</given-names></name><name><surname>Ilter</surname> <given-names>D</given-names></name><name><surname>Elia</surname> <given-names>I</given-names></name><name><surname>Fendt</surname> <given-names>SM</given-names></name><name><surname>Roberts</surname> <given-names>TM</given-names></name><name><surname>Blenis</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation</article-title><source>Current Biology</source><volume>24</volume><fpage>2274</fpage><lpage>2280</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2014.08.007</pub-id><pub-id pub-id-type="pmid">25220053</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dehairs</surname> <given-names>J</given-names></name><name><surname>Talebi</surname> <given-names>A</given-names></name><name><surname>Cherifi</surname> <given-names>Y</given-names></name><name><surname>Swinnen</surname> <given-names>JV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>CRISP-ID: decoding CRISPR mediated indels by Sanger sequencing</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>28973</elocation-id><pub-id pub-id-type="doi">10.1038/srep28973</pub-id><pub-id pub-id-type="pmid">27363488</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Düvel</surname> <given-names>K</given-names></name><name><surname>Yecies</surname> <given-names>JL</given-names></name><name><surname>Menon</surname> <given-names>S</given-names></name><name><surname>Raman</surname> <given-names>P</given-names></name><name><surname>Lipovsky</surname> <given-names>AI</given-names></name><name><surname>Souza</surname> <given-names>AL</given-names></name><name><surname>Triantafellow</surname> <given-names>E</given-names></name><name><surname>Ma</surname> <given-names>Q</given-names></name><name><surname>Gorski</surname> <given-names>R</given-names></name><name><surname>Cleaver</surname> <given-names>S</given-names></name><name><surname>Vander Heiden</surname> <given-names>MG</given-names></name><name><surname>MacKeigan</surname> <given-names>JP</given-names></name><name><surname>Finan</surname> <given-names>PM</given-names></name><name><surname>Clish</surname> <given-names>CB</given-names></name><name><surname>Murphy</surname> <given-names>LO</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Activation of a metabolic gene regulatory network downstream of mTOR complex 1</article-title><source>Molecular Cell</source><volume>39</volume><fpage>171</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.06.022</pub-id><pub-id pub-id-type="pmid">20670887</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebert</surname> <given-names>SM</given-names></name><name><surname>Bullard</surname> <given-names>SA</given-names></name><name><surname>Basisty</surname> <given-names>N</given-names></name><name><surname>Marcotte</surname> <given-names>GR</given-names></name><name><surname>Skopec</surname> <given-names>ZP</given-names></name><name><surname>Dierdorff</surname> <given-names>JM</given-names></name><name><surname>Al-Zougbi</surname> <given-names>A</given-names></name><name><surname>Tomcheck</surname> <given-names>KC</given-names></name><name><surname>DeLau</surname> <given-names>AD</given-names></name><name><surname>Rathmacher</surname> <given-names>JA</given-names></name><name><surname>Bodine</surname> <given-names>SC</given-names></name><name><surname>Schilling</surname> <given-names>B</given-names></name><name><surname>Adams</surname> <given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβ</article-title><source>Journal of Biological Chemistry</source><volume>295</volume><fpage>2787</fpage><lpage>2803</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA119.012095</pub-id><pub-id pub-id-type="pmid">31953319</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gearing</surname> <given-names>LJ</given-names></name><name><surname>Cumming</surname> <given-names>HE</given-names></name><name><surname>Chapman</surname> <given-names>R</given-names></name><name><surname>Finkel</surname> <given-names>AM</given-names></name><name><surname>Woodhouse</surname> <given-names>IB</given-names></name><name><surname>Luu</surname> <given-names>K</given-names></name><name><surname>Gould</surname> <given-names>JA</given-names></name><name><surname>Forster</surname> <given-names>SC</given-names></name><name><surname>Hertzog</surname> <given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CiiiDER: a tool for predicting and analysing transcription factor binding sites</article-title><source>PLOS ONE</source><volume>14</volume><elocation-id>e0215495</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0215495</pub-id><pub-id pub-id-type="pmid">31483836</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffith</surname> <given-names>OW</given-names></name><name><surname>Meister</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1979">1979</year><article-title>Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)</article-title><source>Journal of Biological Chemistry</source><volume>254</volume><fpage>7558</fpage><lpage>7560</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)35980-5</pub-id><pub-id pub-id-type="pmid">38242</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname> <given-names>Y</given-names></name><name><surname>Albuquerque</surname> <given-names>CP</given-names></name><name><surname>Braas</surname> <given-names>D</given-names></name><name><surname>Zhang</surname> <given-names>W</given-names></name><name><surname>Villa</surname> <given-names>GR</given-names></name><name><surname>Bi</surname> <given-names>J</given-names></name><name><surname>Ikegami</surname> <given-names>S</given-names></name><name><surname>Masui</surname> <given-names>K</given-names></name><name><surname>Gini</surname> <given-names>B</given-names></name><name><surname>Yang</surname> <given-names>H</given-names></name><name><surname>Gahman</surname> <given-names>TC</given-names></name><name><surname>Shiau</surname> <given-names>AK</given-names></name><name><surname>Cloughesy</surname> <given-names>TF</given-names></name><name><surname>Christofk</surname> <given-names>HR</given-names></name><name><surname>Zhou</surname> <given-names>H</given-names></name><name><surname>Guan</surname> <given-names>KL</given-names></name><name><surname>Mischel</surname> <given-names>PS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTORC2 regulates amino acid metabolism in Cancer by phosphorylation of the Cystine-Glutamate antiporter xCT</article-title><source>Molecular Cell</source><volume>67</volume><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.05.030</pub-id><pub-id pub-id-type="pmid">28648777</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname> <given-names>E</given-names></name><name><surname>Linher-Melville</surname> <given-names>K</given-names></name><name><surname>Lin</surname> <given-names>HX</given-names></name><name><surname>Singh</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast Cancer cells in response to oxidative stress</article-title><source>Redox Biology</source><volume>5</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2015.03.003</pub-id><pub-id pub-id-type="pmid">25827424</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname> <given-names>J</given-names></name><name><surname>Back</surname> <given-names>SH</given-names></name><name><surname>Hur</surname> <given-names>J</given-names></name><name><surname>Lin</surname> <given-names>YH</given-names></name><name><surname>Gildersleeve</surname> <given-names>R</given-names></name><name><surname>Shan</surname> <given-names>J</given-names></name><name><surname>Yuan</surname> <given-names>CL</given-names></name><name><surname>Krokowski</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Hatzoglou</surname> <given-names>M</given-names></name><name><surname>Kilberg</surname> <given-names>MS</given-names></name><name><surname>Sartor</surname> <given-names>MA</given-names></name><name><surname>Kaufman</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>481</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/ncb2738</pub-id><pub-id pub-id-type="pmid">23624402</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Novoa</surname> <given-names>I</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Wek</surname> <given-names>R</given-names></name><name><surname>Schapira</surname> <given-names>M</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Regulated translation initiation controls stress-induced gene expression in mammalian cells</article-title><source>Molecular Cell</source><volume>6</volume><fpage>1099</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)00108-8</pub-id><pub-id pub-id-type="pmid">11106749</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname> <given-names>HP</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Novoa</surname> <given-names>I</given-names></name><name><surname>Lu</surname> <given-names>PD</given-names></name><name><surname>Calfon</surname> <given-names>M</given-names></name><name><surname>Sadri</surname> <given-names>N</given-names></name><name><surname>Yun</surname> <given-names>C</given-names></name><name><surname>Popko</surname> <given-names>B</given-names></name><name><surname>Paules</surname> <given-names>R</given-names></name><name><surname>Stojdl</surname> <given-names>DF</given-names></name><name><surname>Bell</surname> <given-names>JC</given-names></name><name><surname>Hettmann</surname> <given-names>T</given-names></name><name><surname>Leiden</surname> <given-names>JM</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>An integrated stress response regulates amino acid metabolism and resistance to oxidative stress</article-title><source>Molecular Cell</source><volume>11</volume><fpage>619</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(03)00105-9</pub-id><pub-id pub-id-type="pmid">12667446</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>CH</given-names></name><name><surname>Gong</surname> <given-names>P</given-names></name><name><surname>Hu</surname> <given-names>B</given-names></name><name><surname>Stewart</surname> <given-names>D</given-names></name><name><surname>Choi</surname> <given-names>ME</given-names></name><name><surname>Choi</surname> <given-names>AM</given-names></name><name><surname>Alam</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. implication for heme oxygenase-1 gene regulation</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>20858</fpage><lpage>20865</lpage><pub-id pub-id-type="doi">10.1074/jbc.M101198200</pub-id><pub-id pub-id-type="pmid">11274184</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heigwer</surname> <given-names>F</given-names></name><name><surname>Kerr</surname> <given-names>G</given-names></name><name><surname>Boutros</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>E-CRISP: fast CRISPR target site identification</article-title><source>Nature Methods</source><volume>11</volume><fpage>122</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2812</pub-id><pub-id pub-id-type="pmid">24481216</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname> <given-names>LC</given-names></name><name><surname>Houston</surname> <given-names>KD</given-names></name><name><surname>Hunter</surname> <given-names>DS</given-names></name><name><surname>Fuchs-Young</surname> <given-names>R</given-names></name><name><surname>Zhang</surname> <given-names>Z</given-names></name><name><surname>Wineker</surname> <given-names>RC</given-names></name><name><surname>Walker</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Transdominant suppression of estrogen receptor signaling by progesterone receptor ligands in uterine leiomyoma cells</article-title><source>Molecular and Cellular Endocrinology</source><volume>196</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S0303-7207(02)00230-7</pub-id><pub-id pub-id-type="pmid">12385821</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holz</surname> <given-names>MK</given-names></name><name><surname>Ballif</surname> <given-names>BA</given-names></name><name><surname>Gygi</surname> <given-names>SP</given-names></name><name><surname>Blenis</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events</article-title><source>Cell</source><volume>123</volume><fpage>569</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.10.024</pub-id><pub-id pub-id-type="pmid">16286006</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horton</surname> <given-names>JD</given-names></name><name><surname>Goldstein</surname> <given-names>JL</given-names></name><name><surname>Brown</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver</article-title><source>Journal of Clinical Investigation</source><volume>109</volume><fpage>1125</fpage><lpage>1131</lpage><pub-id pub-id-type="doi">10.1172/JCI0215593</pub-id><pub-id pub-id-type="pmid">11994399</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hudson</surname> <given-names>CC</given-names></name><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Chiang</surname> <given-names>GG</given-names></name><name><surname>Otterness</surname> <given-names>DM</given-names></name><name><surname>Loomis</surname> <given-names>DC</given-names></name><name><surname>Kaper</surname> <given-names>F</given-names></name><name><surname>Giaccia</surname> <given-names>AJ</given-names></name><name><surname>Abraham</surname> <given-names>RT</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin</article-title><source>Molecular and Cellular Biology</source><volume>22</volume><fpage>7004</fpage><lpage>7014</lpage><pub-id pub-id-type="doi">10.1128/MCB.22.20.7004-7014.2002</pub-id><pub-id pub-id-type="pmid">12242281</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggins</surname> <given-names>CJ</given-names></name><name><surname>Mayekar</surname> <given-names>MK</given-names></name><name><surname>Martin</surname> <given-names>N</given-names></name><name><surname>Saylor</surname> <given-names>KL</given-names></name><name><surname>Gonit</surname> <given-names>M</given-names></name><name><surname>Jailwala</surname> <given-names>P</given-names></name><name><surname>Kasoji</surname> <given-names>M</given-names></name><name><surname>Haines</surname> <given-names>DC</given-names></name><name><surname>Quiñones</surname> <given-names>OA</given-names></name><name><surname>Johnson</surname> <given-names>PF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>C/EBPγ is a critical regulator of cellular stress response networks through heterodimerization with ATF4</article-title><source>Molecular and Cellular Biology</source><volume>36</volume><fpage>693</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1128/MCB.00911-15</pub-id><pub-id pub-id-type="pmid">26667036</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jefferies</surname> <given-names>HB</given-names></name><name><surname>Reinhard</surname> <given-names>C</given-names></name><name><surname>Kozma</surname> <given-names>SC</given-names></name><name><surname>Thomas</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Rapamycin selectively represses translation of the &quot;polypyrimidine tract&quot; mRNA family</article-title><source>PNAS</source><volume>91</volume><fpage>4441</fpage><lpage>4445</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.10.4441</pub-id><pub-id pub-id-type="pmid">8183928</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilberg</surname> <given-names>MS</given-names></name><name><surname>Shan</surname> <given-names>J</given-names></name><name><surname>Su</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ATF4-dependent transcription mediates signaling of amino acid limitation</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>20</volume><fpage>436</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2009.05.008</pub-id><pub-id pub-id-type="pmid">19800252</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname> <given-names>H</given-names></name><name><surname>Chandel</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Regulation of redox balance in Cancer and T cells</article-title><source>Journal of Biological Chemistry</source><volume>293</volume><fpage>7499</fpage><lpage>7507</lpage><pub-id pub-id-type="doi">10.1074/jbc.TM117.000257</pub-id><pub-id pub-id-type="pmid">29282291</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kutay</surname> <given-names>U</given-names></name><name><surname>Lipowsky</surname> <given-names>G</given-names></name><name><surname>Izaurralde</surname> <given-names>E</given-names></name><name><surname>Bischoff</surname> <given-names>FR</given-names></name><name><surname>Schwarzmaier</surname> <given-names>P</given-names></name><name><surname>Hartmann</surname> <given-names>E</given-names></name><name><surname>Görlich</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Identification of a tRNA-specific nuclear export receptor</article-title><source>Molecular Cell</source><volume>1</volume><fpage>359</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(00)80036-2</pub-id><pub-id pub-id-type="pmid">9660920</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname> <given-names>HC</given-names></name><name><surname>Baglini</surname> <given-names>CV</given-names></name><name><surname>Lope</surname> <given-names>AL</given-names></name><name><surname>Parkhitko</surname> <given-names>AA</given-names></name><name><surname>Liu</surname> <given-names>HJ</given-names></name><name><surname>Alesi</surname> <given-names>N</given-names></name><name><surname>Malinowska</surname> <given-names>IA</given-names></name><name><surname>Ebrahimi-Fakhari</surname> <given-names>D</given-names></name><name><surname>Saffari</surname> <given-names>A</given-names></name><name><surname>Yu</surname> <given-names>JJ</given-names></name><name><surname>Pereira</surname> <given-names>A</given-names></name><name><surname>Khabibullin</surname> <given-names>D</given-names></name><name><surname>Ogorek</surname> <given-names>B</given-names></name><name><surname>Nijmeh</surname> <given-names>J</given-names></name><name><surname>Kavanagh</surname> <given-names>T</given-names></name><name><surname>Handen</surname> <given-names>A</given-names></name><name><surname>Chan</surname> <given-names>SY</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Oldham</surname> <given-names>WM</given-names></name><name><surname>Diaz-Meco</surname> <given-names>MT</given-names></name><name><surname>Moscat</surname> <given-names>J</given-names></name><name><surname>Sahin</surname> <given-names>M</given-names></name><name><surname>Priolo</surname> <given-names>C</given-names></name><name><surname>Henske</surname> <given-names>EP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>p62/SQSTM1 cooperates with hyperactive mTORC1 to regulate glutathione production, maintain mitochondrial integrity, and promote tumorigenesis</article-title><source>Cancer Research</source><volume>77</volume><fpage>3255</fpage><lpage>3267</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2458</pub-id><pub-id pub-id-type="pmid">28512249</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname> <given-names>PS</given-names></name><name><surname>Chavez</surname> <given-names>JC</given-names></name><name><surname>Pinto</surname> <given-names>JT</given-names></name><name><surname>Coppola</surname> <given-names>G</given-names></name><name><surname>Sun</surname> <given-names>CW</given-names></name><name><surname>Townes</surname> <given-names>TM</given-names></name><name><surname>Geschwind</surname> <given-names>DH</given-names></name><name><surname>Ratan</surname> <given-names>RR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo</article-title><source>Journal of Experimental Medicine</source><volume>205</volume><fpage>1227</fpage><lpage>1242</lpage><pub-id pub-id-type="doi">10.1084/jem.20071460</pub-id><pub-id pub-id-type="pmid">18458112</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laughner</surname> <given-names>E</given-names></name><name><surname>Taghavi</surname> <given-names>P</given-names></name><name><surname>Chiles</surname> <given-names>K</given-names></name><name><surname>Mahon</surname> <given-names>PC</given-names></name><name><surname>Semenza</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression</article-title><source>Molecular and Cellular Biology</source><volume>21</volume><fpage>3995</fpage><lpage>4004</lpage><pub-id pub-id-type="doi">10.1128/MCB.21.12.3995-4004.2001</pub-id><pub-id pub-id-type="pmid">11359907</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>JH</given-names></name><name><surname>Budanov</surname> <given-names>AV</given-names></name><name><surname>Park</surname> <given-names>EJ</given-names></name><name><surname>Birse</surname> <given-names>R</given-names></name><name><surname>Kim</surname> <given-names>TE</given-names></name><name><surname>Perkins</surname> <given-names>GA</given-names></name><name><surname>Ocorr</surname> <given-names>K</given-names></name><name><surname>Ellisman</surname> <given-names>MH</given-names></name><name><surname>Bodmer</surname> <given-names>R</given-names></name><name><surname>Bier</surname> <given-names>E</given-names></name><name><surname>Karin</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies</article-title><source>Science</source><volume>327</volume><fpage>1223</fpage><lpage>1228</lpage><pub-id pub-id-type="doi">10.1126/science.1182228</pub-id><pub-id pub-id-type="pmid">20203043</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>H</given-names></name><name><surname>Lan</surname> <given-names>Z</given-names></name><name><surname>He</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>R</given-names></name><name><surname>Wang</surname> <given-names>F</given-names></name><name><surname>Liu</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>K</given-names></name><name><surname>Cheng</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Sun</surname> <given-names>K</given-names></name><name><surname>Wan</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Peng</surname> <given-names>H</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Jing</surname> <given-names>Y</given-names></name><name><surname>Huang</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Jiang</surname> <given-names>J</given-names></name><name><surname>Zha</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>mTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis</article-title><source>Cell Death &amp; Differentiation</source><volume>26</volume><fpage>2015</fpage><lpage>2028</lpage><pub-id pub-id-type="doi">10.1038/s41418-019-0274-0</pub-id><pub-id pub-id-type="pmid">30760873</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkz114</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lien</surname> <given-names>EC</given-names></name><name><surname>Ghisolfi</surname> <given-names>L</given-names></name><name><surname>Geck</surname> <given-names>RC</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Toker</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT</article-title><source>Science Signaling</source><volume>10</volume><elocation-id>eaao6604</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aao6604</pub-id><pub-id pub-id-type="pmid">29259101</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname> <given-names>XM</given-names></name><name><surname>Blenis</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular mechanisms of mTOR-mediated translational control</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>10</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1038/nrm2672</pub-id><pub-id pub-id-type="pmid">19339977</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname> <given-names>S</given-names></name><name><surname>Qin</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Zheng</surname> <given-names>R</given-names></name><name><surname>Zang</surname> <given-names>C</given-names></name><name><surname>Zhu</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Shi</surname> <given-names>X</given-names></name><name><surname>Taing</surname> <given-names>L</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cistrome data browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D658</fpage><lpage>D662</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw983</pub-id><pub-id pub-id-type="pmid">27789702</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meister</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Selective modification of glutathione metabolism</article-title><source>Science</source><volume>220</volume><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1126/science.6836290</pub-id><pub-id pub-id-type="pmid">6836290</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakazawa</surname> <given-names>MS</given-names></name><name><surname>Keith</surname> <given-names>B</given-names></name><name><surname>Simon</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oxygen availability and metabolic adaptations</article-title><source>Nature Reviews Cancer</source><volume>16</volume><fpage>663</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.84</pub-id><pub-id pub-id-type="pmid">27658636</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname> <given-names>JR</given-names></name><name><surname>Keating</surname> <given-names>AE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Comprehensive identification of human bZIP interactions with coiled-coil arrays</article-title><source>Science</source><volume>300</volume><fpage>2097</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1126/science.1084648</pub-id><pub-id pub-id-type="pmid">12805554</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname> <given-names>JL</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Bae</surname> <given-names>SH</given-names></name><name><surname>Farooqi</surname> <given-names>MS</given-names></name><name><surname>Liang</surname> <given-names>G</given-names></name><name><surname>Hammer</surname> <given-names>RE</given-names></name><name><surname>Goldstein</surname> <given-names>JL</given-names></name><name><surname>Brown</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase</article-title><source>PNAS</source><volume>109</volume><fpage>16184</fpage><lpage>16189</lpage><pub-id pub-id-type="doi">10.1073/pnas.1213343109</pub-id><pub-id pub-id-type="pmid">22927400</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname> <given-names>U</given-names></name><name><surname>Ozcan</surname> <given-names>L</given-names></name><name><surname>Yilmaz</surname> <given-names>E</given-names></name><name><surname>Düvel</surname> <given-names>K</given-names></name><name><surname>Sahin</surname> <given-names>M</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name><name><surname>Hotamisligil</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis</article-title><source>Molecular Cell</source><volume>29</volume><fpage>541</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2007.12.023</pub-id><pub-id pub-id-type="pmid">18342602</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>Y</given-names></name><name><surname>Reyna-Neyra</surname> <given-names>A</given-names></name><name><surname>Philippe</surname> <given-names>L</given-names></name><name><surname>Thoreen</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTORC1 balances cellular amino acid supply with demand for protein synthesis through Post-transcriptional control of ATF4</article-title><source>Cell Reports</source><volume>19</volume><fpage>1083</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.042</pub-id><pub-id pub-id-type="pmid">28494858</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname> <given-names>TR</given-names></name><name><surname>Sengupta</surname> <given-names>SS</given-names></name><name><surname>Harris</surname> <given-names>TE</given-names></name><name><surname>Carmack</surname> <given-names>AE</given-names></name><name><surname>Kang</surname> <given-names>SA</given-names></name><name><surname>Balderas</surname> <given-names>E</given-names></name><name><surname>Guertin</surname> <given-names>DA</given-names></name><name><surname>Madden</surname> <given-names>KL</given-names></name><name><surname>Carpenter</surname> <given-names>AE</given-names></name><name><surname>Finck</surname> <given-names>BN</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway</article-title><source>Cell</source><volume>146</volume><fpage>408</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.034</pub-id><pub-id pub-id-type="pmid">21816276</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porstmann</surname> <given-names>T</given-names></name><name><surname>Santos</surname> <given-names>CR</given-names></name><name><surname>Griffiths</surname> <given-names>B</given-names></name><name><surname>Cully</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>M</given-names></name><name><surname>Leevers</surname> <given-names>S</given-names></name><name><surname>Griffiths</surname> <given-names>JR</given-names></name><name><surname>Chung</surname> <given-names>YL</given-names></name><name><surname>Schulze</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth</article-title><source>Cell Metabolism</source><volume>8</volume><fpage>224</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2008.07.007</pub-id><pub-id pub-id-type="pmid">18762023</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wright</surname> <given-names>J</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raught</surname> <given-names>B</given-names></name><name><surname>Peiretti</surname> <given-names>F</given-names></name><name><surname>Gingras</surname> <given-names>AC</given-names></name><name><surname>Livingstone</surname> <given-names>M</given-names></name><name><surname>Shahbazian</surname> <given-names>D</given-names></name><name><surname>Mayeur</surname> <given-names>GL</given-names></name><name><surname>Polakiewicz</surname> <given-names>RD</given-names></name><name><surname>Sonenberg</surname> <given-names>N</given-names></name><name><surname>Hershey</surname> <given-names>JW</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases</article-title><source>The EMBO Journal</source><volume>23</volume><fpage>1761</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600193</pub-id><pub-id pub-id-type="pmid">15071500</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reiling</surname> <given-names>JH</given-names></name><name><surname>Hafen</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The hypoxia-induced paralogs Scylla and charybdis inhibit growth by down-regulating S6K activity upstream of TSC in <italic>Drosophila</italic></article-title><source>Genes &amp; Development</source><volume>18</volume><fpage>2879</fpage><lpage>2892</lpage><pub-id pub-id-type="doi">10.1101/gad.322704</pub-id><pub-id pub-id-type="pmid">15545626</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname> <given-names>ME</given-names></name><name><surname>Phipson</surname> <given-names>B</given-names></name><name><surname>Wu</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Law</surname> <given-names>CW</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname> <given-names>MD</given-names></name><name><surname>McCarthy</surname> <given-names>DJ</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabò</surname> <given-names>A</given-names></name><name><surname>Kress</surname> <given-names>TR</given-names></name><name><surname>Pelizzola</surname> <given-names>M</given-names></name><name><surname>de Pretis</surname> <given-names>S</given-names></name><name><surname>Gorski</surname> <given-names>MM</given-names></name><name><surname>Tesi</surname> <given-names>A</given-names></name><name><surname>Morelli</surname> <given-names>MJ</given-names></name><name><surname>Bora</surname> <given-names>P</given-names></name><name><surname>Doni</surname> <given-names>M</given-names></name><name><surname>Verrecchia</surname> <given-names>A</given-names></name><name><surname>Tonelli</surname> <given-names>C</given-names></name><name><surname>Fagà</surname> <given-names>G</given-names></name><name><surname>Bianchi</surname> <given-names>V</given-names></name><name><surname>Ronchi</surname> <given-names>A</given-names></name><name><surname>Low</surname> <given-names>D</given-names></name><name><surname>Müller</surname> <given-names>H</given-names></name><name><surname>Guccione</surname> <given-names>E</given-names></name><name><surname>Campaner</surname> <given-names>S</given-names></name><name><surname>Amati</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selective transcriptional regulation by myc in cellular growth control and lymphomagenesis</article-title><source>Nature</source><volume>511</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/nature13537</pub-id><pub-id pub-id-type="pmid">25043028</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname> <given-names>H</given-names></name><name><surname>Sato</surname> <given-names>H</given-names></name><name><surname>Kuriyama-Matsumura</surname> <given-names>K</given-names></name><name><surname>Sato</surname> <given-names>K</given-names></name><name><surname>Maebara</surname> <given-names>K</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Tamba</surname> <given-names>M</given-names></name><name><surname>Itoh</surname> <given-names>K</given-names></name><name><surname>Yamamoto</surname> <given-names>M</given-names></name><name><surname>Bannai</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>44765</fpage><lpage>44771</lpage><pub-id pub-id-type="doi">10.1074/jbc.M208704200</pub-id><pub-id pub-id-type="pmid">12235164</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheuner</surname> <given-names>D</given-names></name><name><surname>Song</surname> <given-names>B</given-names></name><name><surname>McEwen</surname> <given-names>E</given-names></name><name><surname>Liu</surname> <given-names>C</given-names></name><name><surname>Laybutt</surname> <given-names>R</given-names></name><name><surname>Gillespie</surname> <given-names>P</given-names></name><name><surname>Saunders</surname> <given-names>T</given-names></name><name><surname>Bonner-Weir</surname> <given-names>S</given-names></name><name><surname>Kaufman</surname> <given-names>RJ</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Translational control is required for the unfolded protein response and in vivo glucose homeostasis</article-title><source>Molecular Cell</source><volume>7</volume><fpage>1165</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(01)00265-9</pub-id><pub-id pub-id-type="pmid">11430820</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuhmacher</surname> <given-names>M</given-names></name><name><surname>Eick</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dose-dependent regulation of target gene expression and cell proliferation by c-Myc levels</article-title><source>Transcription</source><volume>4</volume><fpage>192</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.4161/trns.25907</pub-id><pub-id pub-id-type="pmid">23989662</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stine</surname> <given-names>ZE</given-names></name><name><surname>Walton</surname> <given-names>ZE</given-names></name><name><surname>Altman</surname> <given-names>BJ</given-names></name><name><surname>Hsieh</surname> <given-names>AL</given-names></name><name><surname>Dang</surname> <given-names>CV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MYC, metabolism, and cancer</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>1024</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0507</pub-id><pub-id pub-id-type="pmid">26382145</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname> <given-names>A</given-names></name><name><surname>Tamayo</surname> <given-names>P</given-names></name><name><surname>Mootha</surname> <given-names>VK</given-names></name><name><surname>Mukherjee</surname> <given-names>S</given-names></name><name><surname>Ebert</surname> <given-names>BL</given-names></name><name><surname>Gillette</surname> <given-names>MA</given-names></name><name><surname>Paulovich</surname> <given-names>A</given-names></name><name><surname>Pomeroy</surname> <given-names>SL</given-names></name><name><surname>Golub</surname> <given-names>TR</given-names></name><name><surname>Lander</surname> <given-names>ES</given-names></name><name><surname>Mesirov</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id><pub-id pub-id-type="pmid">16199517</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>Y</given-names></name><name><surname>El-Chemaly</surname> <given-names>S</given-names></name><name><surname>Taveira-Dasilva</surname> <given-names>A</given-names></name><name><surname>Goldberg</surname> <given-names>HJ</given-names></name><name><surname>Bagwe</surname> <given-names>S</given-names></name><name><surname>Rosas</surname> <given-names>IO</given-names></name><name><surname>Moss</surname> <given-names>J</given-names></name><name><surname>Priolo</surname> <given-names>C</given-names></name><name><surname>Henske</surname> <given-names>EP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Alterations in polyamine metabolism in patients with lymphangioleiomyomatosis and tuberous sclerosis complex 2-Deficient cells</article-title><source>Chest</source><volume>156</volume><fpage>1137</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2019.05.038</pub-id><pub-id pub-id-type="pmid">31299246</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname> <given-names>GV</given-names></name><name><surname>Tran</surname> <given-names>C</given-names></name><name><surname>Mellinghoff</surname> <given-names>IK</given-names></name><name><surname>Welsbie</surname> <given-names>DS</given-names></name><name><surname>Chan</surname> <given-names>E</given-names></name><name><surname>Fueger</surname> <given-names>B</given-names></name><name><surname>Czernin</surname> <given-names>J</given-names></name><name><surname>Sawyers</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney Cancer</article-title><source>Nature Medicine</source><volume>12</volume><fpage>122</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1038/nm1337</pub-id><pub-id pub-id-type="pmid">16341243</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thoreen</surname> <given-names>CC</given-names></name><name><surname>Chantranupong</surname> <given-names>L</given-names></name><name><surname>Keys</surname> <given-names>HR</given-names></name><name><surname>Wang</surname> <given-names>T</given-names></name><name><surname>Gray</surname> <given-names>NS</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A unifying model for mTORC1-mediated regulation of mRNA translation</article-title><source>Nature</source><volume>485</volume><fpage>109</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nature11083</pub-id><pub-id pub-id-type="pmid">22552098</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrence</surname> <given-names>ME</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Nutrient sensing in cancer</article-title><source>Annual Review of Cancer Biology</source><volume>2</volume><fpage>251</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1146/annurev-cancerbio-030617-050329</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valvezan</surname> <given-names>AJ</given-names></name><name><surname>Turner</surname> <given-names>M</given-names></name><name><surname>Belaid</surname> <given-names>A</given-names></name><name><surname>Lam</surname> <given-names>HC</given-names></name><name><surname>Miller</surname> <given-names>SK</given-names></name><name><surname>McNamara</surname> <given-names>MC</given-names></name><name><surname>Baglini</surname> <given-names>C</given-names></name><name><surname>Housden</surname> <given-names>BE</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name><name><surname>Kwiatkowski</surname> <given-names>DJ</given-names></name><name><surname>Asara</surname> <given-names>JM</given-names></name><name><surname>Henske</surname> <given-names>EP</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTORC1 couples nucleotide synthesis to nucleotide demand resulting in a targetable metabolic vulnerability</article-title><source>Cancer Cell</source><volume>32</volume><fpage>624</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.09.013</pub-id><pub-id pub-id-type="pmid">29056426</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valvezan</surname> <given-names>AJ</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Molecular logic of mTORC1 signalling as a metabolic rheostat</article-title><source>Nature Metabolism</source><volume>1</volume><fpage>321</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1038/s42255-019-0038-7</pub-id><pub-id pub-id-type="pmid">32694720</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vattem</surname> <given-names>KM</given-names></name><name><surname>Wek</surname> <given-names>RC</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells</article-title><source>PNAS</source><volume>101</volume><fpage>11269</fpage><lpage>11274</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400541101</pub-id><pub-id pub-id-type="pmid">15277680</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname> <given-names>M</given-names></name><name><surname>Poortinga</surname> <given-names>G</given-names></name><name><surname>Hannan</surname> <given-names>KM</given-names></name><name><surname>Pearson</surname> <given-names>RB</given-names></name><name><surname>Hannan</surname> <given-names>RD</given-names></name><name><surname>McArthur</surname> <given-names>GA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation</article-title><source>Blood</source><volume>112</volume><fpage>2305</fpage><lpage>2317</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-09-111856</pub-id><pub-id pub-id-type="pmid">18621930</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname> <given-names>P</given-names></name><name><surname>Ron</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The unfolded protein response: from stress pathway to homeostatic regulation</article-title><source>Science</source><volume>334</volume><fpage>1081</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1126/science.1209038</pub-id><pub-id pub-id-type="pmid">22116877</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walz</surname> <given-names>S</given-names></name><name><surname>Lorenzin</surname> <given-names>F</given-names></name><name><surname>Morton</surname> <given-names>J</given-names></name><name><surname>Wiese</surname> <given-names>KE</given-names></name><name><surname>von Eyss</surname> <given-names>B</given-names></name><name><surname>Herold</surname> <given-names>S</given-names></name><name><surname>Rycak</surname> <given-names>L</given-names></name><name><surname>Dumay-Odelot</surname> <given-names>H</given-names></name><name><surname>Karim</surname> <given-names>S</given-names></name><name><surname>Bartkuhn</surname> <given-names>M</given-names></name><name><surname>Roels</surname> <given-names>F</given-names></name><name><surname>Wüstefeld</surname> <given-names>T</given-names></name><name><surname>Fischer</surname> <given-names>M</given-names></name><name><surname>Teichmann</surname> <given-names>M</given-names></name><name><surname>Zender</surname> <given-names>L</given-names></name><name><surname>Wei</surname> <given-names>CL</given-names></name><name><surname>Sansom</surname> <given-names>O</given-names></name><name><surname>Wolf</surname> <given-names>E</given-names></name><name><surname>Eilers</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles</article-title><source>Nature</source><volume>511</volume><fpage>483</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1038/nature13473</pub-id><pub-id pub-id-type="pmid">25043018</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfson</surname> <given-names>RL</given-names></name><name><surname>Chantranupong</surname> <given-names>L</given-names></name><name><surname>Saxton</surname> <given-names>RA</given-names></name><name><surname>Shen</surname> <given-names>K</given-names></name><name><surname>Scaria</surname> <given-names>SM</given-names></name><name><surname>Cantor</surname> <given-names>JR</given-names></name><name><surname>Sabatini</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Sestrin2 is a leucine sensor for the mTORC1 pathway</article-title><source>Science</source><volume>351</volume><fpage>43</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1126/science.aab2674</pub-id><pub-id pub-id-type="pmid">26449471</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wortel</surname> <given-names>IMN</given-names></name><name><surname>van der Meer</surname> <given-names>LT</given-names></name><name><surname>Kilberg</surname> <given-names>MS</given-names></name><name><surname>van Leeuwen</surname> <given-names>FN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Surviving stress: modulation of ATF4-Mediated stress responses in normal and malignant cells</article-title><source>Trends in Endocrinology &amp; Metabolism</source><volume>28</volume><fpage>794</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.tem.2017.07.003</pub-id><pub-id pub-id-type="pmid">28797581</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Wei</surname> <given-names>L</given-names></name><name><surname>Fan</surname> <given-names>F</given-names></name><name><surname>Ji</surname> <given-names>S</given-names></name><name><surname>Zhang</surname> <given-names>S</given-names></name><name><surname>Geng</surname> <given-names>J</given-names></name><name><surname>Hong</surname> <given-names>L</given-names></name><name><surname>Fan</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Q</given-names></name><name><surname>Tian</surname> <given-names>J</given-names></name><name><surname>Jiang</surname> <given-names>M</given-names></name><name><surname>Sun</surname> <given-names>X</given-names></name><name><surname>Jin</surname> <given-names>C</given-names></name><name><surname>Yin</surname> <given-names>ZY</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Qin</surname> <given-names>F</given-names></name><name><surname>Lin</surname> <given-names>KH</given-names></name><name><surname>Yu</surname> <given-names>JS</given-names></name><name><surname>Deng</surname> <given-names>X</given-names></name><name><surname>Wang</surname> <given-names>HR</given-names></name><name><surname>Zhao</surname> <given-names>B</given-names></name><name><surname>Johnson</surname> <given-names>RL</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Zhou</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Integration of hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6239</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7239</pub-id><pub-id pub-id-type="pmid">25695629</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname> <given-names>Y</given-names></name><name><surname>Hill</surname> <given-names>MC</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Deshmukh</surname> <given-names>V</given-names></name><name><surname>Martin</surname> <given-names>TJ</given-names></name><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Martin</surname> <given-names>JF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis</article-title><source>Genes &amp; Development</source><volume>33</volume><fpage>1491</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1101/gad.329763.119</pub-id><pub-id pub-id-type="pmid">31558567</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>WS</given-names></name><name><surname>Stockwell</surname> <given-names>BR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring Cancer cells</article-title><source>Chemistry &amp; Biology</source><volume>15</volume><fpage>234</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2008.02.010</pub-id><pub-id pub-id-type="pmid">18355723</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname> <given-names>P</given-names></name><name><surname>Mimura</surname> <given-names>J</given-names></name><name><surname>Okada</surname> <given-names>T</given-names></name><name><surname>Sato</surname> <given-names>H</given-names></name><name><surname>Liu</surname> <given-names>T</given-names></name><name><surname>Maruyama</surname> <given-names>A</given-names></name><name><surname>Ohyama</surname> <given-names>C</given-names></name><name><surname>Itoh</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition</article-title><source>Molecular and Cellular Biology</source><volume>34</volume><fpage>3421</fpage><lpage>3434</lpage><pub-id pub-id-type="doi">10.1128/MCB.00221-14</pub-id><pub-id pub-id-type="pmid">25002527</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>G</given-names></name><name><surname>Wang</surname> <given-names>LG</given-names></name><name><surname>Han</surname> <given-names>Y</given-names></name><name><surname>He</surname> <given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS: A Journal of Integrative Biology</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarei</surname> <given-names>M</given-names></name><name><surname>Du</surname> <given-names>H</given-names></name><name><surname>Nassar</surname> <given-names>AH</given-names></name><name><surname>Yan</surname> <given-names>RE</given-names></name><name><surname>Giannikou</surname> <given-names>K</given-names></name><name><surname>Johnson</surname> <given-names>SH</given-names></name><name><surname>Lam</surname> <given-names>HC</given-names></name><name><surname>Henske</surname> <given-names>EP</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Asara</surname> <given-names>J</given-names></name><name><surname>Kwiatkowski</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion</article-title><source>Journal of Experimental Medicine</source><volume>216</volume><fpage>2635</fpage><lpage>2652</lpage><pub-id pub-id-type="doi">10.1084/jem.20190251</pub-id><pub-id pub-id-type="pmid">31506280</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Nicholatos</surname> <given-names>J</given-names></name><name><surname>Dreier</surname> <given-names>JR</given-names></name><name><surname>Ricoult</surname> <given-names>SJ</given-names></name><name><surname>Widenmaier</surname> <given-names>SB</given-names></name><name><surname>Hotamisligil</surname> <given-names>GS</given-names></name><name><surname>Kwiatkowski</surname> <given-names>DJ</given-names></name><name><surname>Manning</surname> <given-names>BD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Coordinated regulation of protein synthesis and degradation by mTORC1</article-title><source>Nature</source><volume>513</volume><fpage>440</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/nature13492</pub-id><pub-id pub-id-type="pmid">25043031</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>R</given-names></name><name><surname>Wan</surname> <given-names>C</given-names></name><name><surname>Mei</surname> <given-names>S</given-names></name><name><surname>Qin</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>Q</given-names></name><name><surname>Sun</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>CH</given-names></name><name><surname>Brown</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Meyer</surname> <given-names>CA</given-names></name><name><surname>Liu</surname> <given-names>XS</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cistrome data browser: expanded datasets and new tools for gene regulatory analysis</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D729</fpage><lpage>D735</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1094</pub-id><pub-id pub-id-type="pmid">30462313</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname> <given-names>H</given-names></name><name><surname>Chiles</surname> <given-names>K</given-names></name><name><surname>Feldser</surname> <given-names>D</given-names></name><name><surname>Laughner</surname> <given-names>E</given-names></name><name><surname>Hanrahan</surname> <given-names>C</given-names></name><name><surname>Georgescu</surname> <given-names>MM</given-names></name><name><surname>Simons</surname> <given-names>JW</given-names></name><name><surname>Semenza</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate Cancer cells: implications for tumor angiogenesis and therapeutics</article-title><source>Cancer Research</source><volume>60</volume><fpage>1541</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">10749120</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zirin</surname> <given-names>J</given-names></name><name><surname>Ni</surname> <given-names>X</given-names></name><name><surname>Sack</surname> <given-names>LM</given-names></name><name><surname>Yang-Zhou</surname> <given-names>D</given-names></name><name><surname>Hu</surname> <given-names>Y</given-names></name><name><surname>Brathwaite</surname> <given-names>R</given-names></name><name><surname>Bulyk</surname> <given-names>ML</given-names></name><name><surname>Elledge</surname> <given-names>SJ</given-names></name><name><surname>Perrimon</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Interspecies analysis of MYC targets identifies tRNA synthetases as mediators of growth and survival in MYC-overexpressing cells</article-title><source>PNAS</source><volume>116</volume><fpage>14614</fpage><lpage>14619</lpage><pub-id pub-id-type="doi">10.1073/pnas.1821863116</pub-id><pub-id pub-id-type="pmid">31262815</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63326.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger J</given-names></name><role>Reviewing Editor</role><aff><institution>University of Massachusetts Medical School</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Shen</surname><given-names>Kuang</given-names> </name><role>Reviewer</role><aff><institution>UMASS Medical School</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>Torrence and colleagues explored the differential activation of ATF4 by the integrated stress response (ISR) and mTORC1. They presented strong genetic evidence that ISR and mTORC1 independently stimulate ATF4, and different sets of downstream targets are activated when ATF4 is stimulated by ISR or mTORC1. They further performed biochemical and metabolomic experiments to demonstrate that ATF4 triggered by mTORC1 induces protein synthesis and amino acid uptake, which is consistent with the canonical function of the mTORC1 pathway. This manuscript presents high quality data that support the major conclusion.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by David Ron as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is &quot;in revision at <italic>eLife</italic>&quot;. Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)</p><p>Summary:</p><p>It is known that ATF4 plays a role in both the integrated stress response (ISR) and mTORC1 signaling. However, the relative roles of ATF4 in these two processes is not understood. Here the authors compare ISR and TORC1 responses of wild-type and ATF4<sup>-/-</sup> cells. The authors conclude that mTORC1 stimulates only a sub-set of ATF4-dependent ISR target genes. These mTOR pathways include amino acid synthesis, uptake, and tRNA charging. The authors also report a role for mTORC1 and ATF4-dependent cystine uptake and glutathione synthesis. The data presented extend previous reports in the field (PMID: 26912861, PMID: 28494858). However, a number of points remain to be addressed to complete this study.</p><p>Essential revisions:</p><p>1) This study identifies an overlap between ATF4-dependent gene expression in response to the ISR and mTORC1 pathways. However, the analysis falls short of providing insight into the underlying mechanism. What accounts for the different subsets of ATF4-dependent gene expression under these conditions? The Discussion section of the manuscript proposes that it might be due to differences in ATF4 expression (high vs. low) or to the differential engagement of ATF4 heterodimeric partners, but no experimental tests of these predictions are presented. The difference could also be due to combinatorial actions of ATF4 with other transcription factors on gene promoters that are differentially activated by ISR vs. mTORC1. Comparative bioinformatics analysis of the promotors corresponding to the differentially expressed genes would be helpful. Moreover, biochemical analysis of ATF4 under these conditions is required, including analysis of heteromeric partners and DNA binding analysis.</p><p>2) Figure 2A and E. The authors need to explain the discordance between the RNA and protein levels. Densitometric analysis of the protein blots may be helpful. Moreover, the authors should show protein levels from the subset of &quot;Amino acid transporter&quot; genes as they did with &quot;tRNA Charging&quot; genes and &quot;amino acid synthesis&quot; genes in the Figure 2D and E.</p><p>3) MYC controls several amino acid transporters (PMID: 32022686). Since MYC can be activated downstream of mTORC1, the authors should examine MYC's contribution to amino acid transporter expression in the <italic>Tsc2<sup>-/-</sup></italic> cells.</p><p>4) Figure 3D. The authors need to show the protein levels of the ATF4 targets (as they did in Figure 3C) to demonstrate resistance to rapamycin at the protein level. This is important because of the inconsistencies between RNA and protein expression shown in Figure 2A and E.</p><p>5) Figure 5B, C. The authors should show the protein levels of the Slc7a11 and <italic>Slc3a2</italic> to demonstrate the differential sensitivity to rapamycin in the different cell lines.</p><p>6) Figure 5E. The authors conclude that there is a critical role for mTORC1 in controlling cystine uptake through ATF4. However, the addition of cystine fully rescues cell growth in ATF4-depleted cells. How is that possible if the transporter levels would be reduced because of the lack of ATF4?</p><p>7) Figure 6H, the authors claim that glutathione levels were restored in <italic>Atf4<sup>-/-</sup></italic> cells upon exogenous expression of ATF4 through the activation of <italic>Slc7a11</italic>. However, ATF4 also regulates the subunits of glutamate-cysteine ligase levels (PMID: 17297441). How are the Gclc and Gclm levels in <italic>Atf4<sup>-/-</sup></italic> cells in Figure 6G and H? The authors should measure these proteins in total ATF4-KO instead of using siRNA (Figure 7—figure supplement 1E).</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.63326.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) This study identifies an overlap between ATF4-dependent gene expression in response to the ISR and mTORC1 pathways. However, the analysis falls short of providing insight into the underlying mechanism. What accounts for the different subsets of ATF4-dependent gene expression under these conditions? The Discussion section of the manuscript proposes that it might be due to differences in ATF4 expression (high vs. low) or to the differential engagement of ATF4 heterodimeric partners, but no experimental tests of these predictions are presented. The difference could also be due to combinatorial actions of ATF4 with other transcription factors on gene promoters that are differentially activated by ISR vs. mTORC1. Comparative bioinformatics analysis of the promotors corresponding to the differentially expressed genes would be helpful. Moreover, biochemical analysis of ATF4 under these conditions is required, including analysis of heteromeric partners and DNA binding analysis.</p></disp-quote><p>This important question is unknown for the majority of studies on ATF4, which can be activated by many distinct upstream stress signals, in addition to growth factor signaling through mTORC1, to elicit both specific and overlapping gene responses. Given that the ATF4-dependent targets found to be shared between the ISR and mTORC1 signaling in our analyses represent many of the canonically reported ATF4 targets in other settings, we hypothesized and discussed in our original submission that these might represent those targets that are most sensitive to induction of ATF4 protein levels. Consistent with this idea, an analysis of the 774 genes significantly induced by tunicamycin in an ATF4-dependent manner (Figure 1—source data 1) reveal that the 61 genes also significantly induced by insulin and sensitive to rapamycin are greatly enriched amongst the top-100 most significantly induced by tunicamycin (depicted in red in the new Figure 1E, with individual genes denoted in Figure 1—source data 1).</p><p>New Figure 2: As suggested, we also used two bioinformatic approaches to analyze the promoters of these ATF4-dependent gene targets. First, we used the CiiiDER tool to predict DNA-binding motifs of transcription factors in the promoters of the 61 ATF4-dependent genes shared between the ISR and mTORC1 signaling versus the top-200 ISR only genes. This worked quite well and revealed that C/EBP-binding motifs are the most enriched amongst the shared genes, while binding motifs for the TEAD family of transcription factors were enriched for the ISR only genes (new Figure 2A). This latter observation is interesting in light of recent studies indicating that TEAD and its binding partners YAP/TAZ, downstream targets of the Hippo pathway, are activated by ER stress and can engage UPR targets (PMID: 25695629; PMID: 31558567). Our second unbiased analysis employed the Cistrome database of published and curated genome-wide ChIP-seq studies to determine whether specific transcription factors have been found to engage promoters of the 61 genes with shared regulation. Once again, the C/EBP family of transcription factors were found among ChIP-seq studies to most commonly bind to the promoters of these genes (new Figure 2B).</p><p>ATF4 can heterodimerize with the entire C/EBP family (PMID: 12805554). Thus, to follow up on our bioinformatic observations with functional assays, we used siRNA-mediated knockdown of individual C/EBP isoforms (α, β, δ, γ) and ATF4 and examined expression of representative genes from distinct functional categories (<italic>Mthfd2</italic>, <italic>Slc7a5</italic>, <italic>Aars</italic>) from the list of 61 ATF4-dependent targets shared in their regulation by mTORC1 and the ISR. This analysis revealed a high degree of cross regulation between these different isoforms and ATF4 in regulation of their own transcripts, which made it difficult to assess the direct effects of one or more of these C/EBP family members on downstream targets (new Figure 2C). Unfortunately, we were unable to identify reliable isoform-specific C/EBP antibodies that gave clear and reproducible signals by immunoblot or IP from MEF lysates, with antibodies tested using siRNA-mediated knockdowns as controls for the proper bands. To varying degrees, C/EBPβ, δ, and γ knockdowns all decreased expression of the targets tested, but only C/EBPγ did so for every gene without influencing ATF4 protein levels (new Figure 2C, D). Interestingly, many of the 61 shared genes identified overlap with those found previously to be regulated by ATF4 through heterodimerization with C/EBPγ in response to amino acid deprivation stress (PMID: 26667036). Thus, we used siRNA-mediated knockdown of ATF4 or C/EBPγ to determine the effects on the insulin and rapamycin response of these representative targets (new Figure 2D). These data demonstrated that C/EBPγ was required for induction of these genes by insulin and was also required for the insulin-stimulated increase in ATF4 gene expression. Together, our new bioinformatic analyses and functional data suggest that C/EBPγ engagement is responsible for at least part of the ATF4-dependent gene expression program shared between mTORC1 signaling and the ISR. However, as shown by use of the rapamycin-resistant ATF4 cDNA, the mTORC1-mediated regulation of these gene targets is primarily through effects on ATF4 protein levels.</p><disp-quote content-type="editor-comment"><p>2) Figure 2A and E. The authors need to explain the discordance between the RNA and protein levels. Densitometric analysis of the protein blots may be helpful. Moreover, the authors should show protein levels from the subset of &quot;Amino acid transporter&quot; genes as they did with &quot;tRNA Charging&quot; genes and &quot;amino acid synthesis&quot; genes in the Figure 2D and E.</p></disp-quote><p>Transcript and protein levels are often in discordance, given that protein abundance is independently influenced by varying rates of translation, stability, and degradation. Quantification of these blots was facilitated by use of a LICOR Odyssey Imaging System, which provides linear quantification rather than that derived from enzyme-linked blotting methods. Corresponding protein quantification of the blots in Figure 2D-E is now provided as new Figure 3—figure supplement 1C-D. We tested antibodies, together with siRNA controls for specificity, for multiple amino acid transporters found to be regulated at the transcript level by mTORC1 signaling through ATF4, including SLC7A5, SLC3A2/CD98, SLC1A5, and SLC7A11. Some of these antibodies work for blotting of human protein extracts, but unfortunately, only SLC7A11 gave a specific band that was decreased with siRNAs in MEFs (new Figure 6—figure supplement 1A), see comment 5 below.</p><disp-quote content-type="editor-comment"><p>3) MYC controls several amino acid transporters (PMID: 32022686). Since MYC can be activated downstream of mTORC1, the authors should examine MYC's contribution to amino acid transporter expression in the Tsc2<sup>-/-</sup> cells.</p></disp-quote><p>We expanded our analysis of ATF4 gene targets to include both amino acid transporters (<italic>Slc7a11</italic>, <italic>Slc7a5</italic>, <italic>Slc3a2</italic>, and <italic>Slc1a5</italic>) and genes of non-essential amino acid synthesis (<italic>Psat1</italic> and <italic>Mthfd2</italic>), some of which have been found to be regulated by Myc in other settings. While a few of these were found to be significantly reduced with siRNA-mediated knockdown of c-Myc, in all cases ATF4 knockdown more strongly and significantly reduced their expression (new Figure 3—figure supplement 1L).</p><disp-quote content-type="editor-comment"><p>4) Figure 3D. The authors need to show the protein levels of the ATF4 targets (as they did in Figure 3C) to demonstrate resistance to rapamycin at the protein level. This is important because of the inconsistencies between RNA and protein expression shown in Figure 2A and E.</p></disp-quote><p>As mentioned with comment 2 above, we do not expect the RNA and protein expression to match in degree of changes. However, we have confirmed by immunoblot that the levels of proteins encoded by specific ATF4 gene targets are indeed elevated and rapamycin resistant in ATF4 knockout cells reconstituted with the ATF4 cDNA lacking its 5’UTR, but not the ATF4-DBD mutant version of this cDNA (new Figure 4—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>5) Figure 5B, C. The authors should show the protein levels of the Slc7a11 and Slc3a2 to demonstrate the differential sensitivity to rapamycin in the different cell lines.</p></disp-quote><p>After testing several different commercially available antibodies, we were able to find SLC7a11 antibodies that specifically and reliably recognized this protein in either mouse or human cell protein extracts, and an SLC3A2/CD98 antibody that works for human proteins. SiRNA validation of the SLC7A11 antibody in MEFs is provided in new Figure 6—figure supplement 1A. Consistent with the mTORC1-regulated changes in transcript levels described in mouse and human lines in the original manuscript, we find that mTOR inhibitors significantly decrease SLC7A11 protein levels in <italic>Tsc2<sup>-/-</sup></italic> MEFs (new Figure 6D and quantified in new Figure 6—figure supplement 1B), and in wild-type MEFs, insulin stimulates an increase in SLC7A11 protein in a manner that is sensitive to mTOR inhibitors (new Figure 6E and quantified in new Figure 6—figure supplement 1C). The protein levels of SLC7A11, but not SLC3A2/CD98, are also significantly sensitive to mTOR inhibitors in human LNCaP and PC3 cells (new Figure 6F and Figure 6—figure supplement 1F-H). As above, these blots were quantified using the LICOR system.</p><disp-quote content-type="editor-comment"><p>6) Figure 5E. The authors conclude that there is a critical role for mTORC1 in controlling cystine uptake through ATF4. However, the addition of cystine fully rescues cell growth in ATF4-depleted cells. How is that possible if the transporter levels would be reduced because of the lack of ATF4?</p></disp-quote><p>There is apparent confusion between cysteine (Cys) and cystine (Cys<sub>2</sub>) reflected by this comment. The figure (now Figure 6H) and accompanying text describe rescue of proliferation by cysteine but not cystine, as also observed in Figure 7F for glutathione levels. As noted in the text, cysteine gets into cells through neutral amino acid transporters that are not regulated by ATF4, as the SLC7A11-dependent transport of cystine is.</p><disp-quote content-type="editor-comment"><p>7) Figure 6H, the authors claim that glutathione levels were restored in Atf4<sup>-/-</sup> cells upon exogenous expression of ATF4 through the activation of Slc7a11. However, ATF4 also regulates the subunits of glutamate-cysteine ligase levels (PMID: 17297441). How are the Gclc and Gclm levels in Atf4<sup>-/-</sup> cells in Figure 6G and H? The authors should measure these proteins in total ATF4-KO instead of using siRNA (Figure 7—figure supplement 1E).</p></disp-quote><p>Consistent with our data shown regarding rapamycin-sensitive expression of Gclc and Gclm transcripts, which were unaffected by siRNA-mediated knockdown of ATF4 (Figure 7—figure supplement 1D-E), only minor changes in GCLC and GCLM protein levels were detected with ATF4 knockout in wild-type cells or knockout and reconstitution in <italic>Tsc2<sup>-/-</sup></italic> cells (Figure 7—figure supplement 1F-G). Insulin stimulated a modest increase in the levels of these proteins in both wild-type and ATF4 knockout MEFs, in a manner sensitive to mTOR inhibitors, but mTORC1-mediated effects on these proteins were not apparent in <italic>Tsc2<sup>-/-</sup></italic> cells with or without ATF4. Thus, in these settings, we do not observe reproducible effects on levels of GCL enzyme complex components that would explain the observed effects of mTORC1 signaling, ATF4, SLC7A11, and cysteine on intracellular glutathione abundance, detailed in Figure 7.</p></body></sub-article></article>